The Online Seminar shows the Possibilities of the use of Desktop-Sharing Software. The Online-Seminar is free of charge an will contain the following topic.
How to Setup the Software.
Cost of the Software
Usage in the Sales and Marketing area.
The Webinar will held on request\, the duration is approx. 30 Minutes
Further Information to the Online-Seminar
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120402T220000Z DTEND;VALUE=DATE-TIME:20120724T213000Z UID:http://www.webinarcentral.net/content/business-mastery-series URL;VALUE=URI:http://www.webinarcentral.net/content/business-mastery-series SUMMARY:Business Mastery Series DESCRIPTION:Learn more\: www.practicepaysolutions.com/mastery
Join us for a free series of one-hour webinars with the a team of industry experts! We're presenting the less-covered\, critical issues for small business owners\, so you can reduce the time you spend on set-up and administration-- and focus on what really matters.
Can't attend live? We'll send you the call recordings so you can access valuable information and share the event with your community!
April 2nd\: The Joy of Productivity with George Kao
April 16th\: How to Create Profitable Referral Partnerships with Robert Notter
April 24th\: Say Bye-Bye to Your Boring Bio with Nancy Juetten
May 15th\: From Contacts to Contracts with Caterina Rando
May 22nd\: Red Fire Profitability with Liz Goodgold
June 5th\: Developing Contracts &\; Service Agreements with Tasha Cooper Coleman
June 19th\: Outsourcing Secrets with Travis Greenlee
July 10th\: Your Money Relationship = Your Business Success with Helen Kim
July 24th\: How to Play a Bigger Marketing Game with Fabienne Fredrickson
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120417T150300Z DTEND;VALUE=DATE-TIME:20120814T150300Z UID:http://www.webinarcentral.net/content/play-therapy-webinar-series URL;VALUE=URI:http://www.webinarcentral.net/content/play-therapy-webinar-series SUMMARY:Play Therapy Webinar Series DESCRIPTION:Allan Gonsher and Kids Inc are pleased to a offer a series of Play Therapy Webinars. If your work with children\, or want to work with children\, these are workshops that you can not afford to miss. Each webinar workshop offers one hour of continuing education credit.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120524T150000Z DTEND;VALUE=DATE-TIME:20120525T230000Z UID:http://www.webinarcentral.net/content/z%E2%80%99s-microbial-control-monitoring-and-validation-pharmaceutical-water-systems-0 URL;VALUE=URI:http://www.webinarcentral.net/content/z%E2%80%99s-microbial-control-monitoring-and-validation-pharmaceutical-water-systems-0 SUMMARY:The A to Z’s of Microbial Control\, Monitoring and validation of Pharmaceutical Water Systems DESCRIPTION:Course Description\:
All pharmaceutical\, biologics\, and medical device facilities are likely to have high purity water systems. In spite of this purity\, microorganisms can flourish within these systems and lead to undesirable contamination of facility processes and their products. Of all the individuals at the facility who should understand the microorganisms in water systems and how best to monitor and control and them\, it should be the site’s microbiologists. Sadly\, this is often not the case due to the lack of familiarity with biofilm and its impact on water system sampling\, testing\, sanitization\, and routine maintenance.
This course is designed to provide a microbiology-focused education about all aspects of water systems and how biofilm manages to thrive there. Prior microbiological education or training\, though a plus\, is not a requirement. The instructor can provide the necessary background needed to understand this very important subject matter. This understanding is essential to the proper design\, validation\, operation\, monitoring\, and maintenance of a high purity water system. Without this understanding\, water system control consists of a set of rules that often don’t work and can cause very costly system downtime or even product recalls.
Learning Objectives \:-
At the completion of the course\, attendees will be able to\:
This 90-minute webinar will help you understand the problems that can occur with statements by pharmaceutical manufacturers directed to off-label uses of pharmaceuticals.
Why Should You Attend\:
Off-label uses cannot be legally promoted. Promoting off-label uses may be viewed by FDA as actionable under the False Claims Act. Criminal and civil liabilities can be substantial for manufacturers. One recent settlement agreement with FDA went into the hundreds of millions of dollars.
Social media increases the chance for interaction between pharmaceutical manufacturers and patients (and others) like never before. Manufacturers are increasing in a position to responding to unsolicited requests for off-label information about prescription drugs and medical devices. The Federal Courts have offered some protections via interpretations of the First Amendment right to free speech.
This 90-minute training will help you understand the problems that can occur with statements by pharmaceutical manufacturers directed to off-label uses of pharmaceuticals. We will also discuss examples of recent cases dealing with communications about off-label uses of pharmaceuticals.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120524T160000Z DTEND;VALUE=DATE-TIME:20120524T173000Z UID:http://www.webinarcentral.net/content/overview-risk-management-and-risk-analysis-techniques-clinical-trials-webinar-complianceonli URL;VALUE=URI:http://www.webinarcentral.net/content/overview-risk-management-and-risk-analysis-techniques-clinical-trials-webinar-complianceonli SUMMARY:An Overview of Risk Management and Risk Analysis Techniques in Clinical Trials - Webinar By ComplianceOnline DESCRIPTION:This webinar will provide you with an overview of risk factors in clinical trials and discuss possible ways to mitigate\, control\, assess impact\, and prevent them in your trial.
Why Should You Attend \:
If you are currently involved in clinical trials either as a CRA\, project manager\, investigator or sponsor\, this webinar will provide you with an overview of risk factors in clinical trials and possible ways to mitigate\, control\, assess impact\, and prevent them in your trial. We would discuss the key elements of risk management such as planning\, identification\, quantification\, action\, measurement\, outcome assessment\, and post-implementation review of various types of risks. Also discussed will be best practices for risk analysis and prospective planning in the project plan. At the end of the course\, you would be able to review your current project plan for potential issues or help address these factors in the future clinical trial project plans that you may create.
Learning Objectives\:
At the end of the seminar\, the attendees will be familiar with the following\:
Overview\: Analytical methods should be validated to ensure reliability\, consistency and accuracy of analytical data. Method validation has been a requirement of FDA and international regulations and accreditation standards such as ISO 17025 since many years. Most often the theory is well understood but there are many questions when validation experiments are designed\, conducted\, and documented.
This webinar will provide a good understanding on how to effectively prepare\, conducts and document method validation experiments for FDA and ISO 17025 compliance.
Reference material for easy implementation\:
SOP\: Validation of Analytical Methods
Checklist\: Validation of Analytical Methods
65-page Primer\: Validation of Analytical Methods
Areas Covered in the Session\:
FDA regulations and guidelines
Examples of warning letters and how to avoid them
USP Chapters and ICH Guides
Developing an SOP for method validation
Development of a validation plan for success
Prerequisites for method validation
Defining the minimum number of validation experiments that satisfy ICH\, FDA and USP
Defining test conditions and acceptance limits
Verification of compendial methods according to USP <\;1226>\;
To revalidate or not after method changes
Transferring a method to routine according to USP <\;1224>\;
Seven most common method validation pitfalls and how to avoid them
Using software for automated method validation
Documentation for the FDA and for other agencies
Who Will Benefit\:
Laboratory managers and supervisors
GLP/GCP/GMP auditors
ISO 17025 auditors
QA/QC managers and personnel
Analysts and other laboratory staff
Regulatory affairs
Training departments
Consultants
Ludwig Huber\, Ph.D.\, is Director of Labcompliance and Chief Advisor for global FDA compliance at Agilent Technologies. He is the editor of Labcompliance\, the global on-line resource for validation and compliance issues for laboratories. He is the author of the books \\"Validation and Qualification in Analytical Laboratories\, and \\"Validation of Computerized Analytical and Networked Systems\\"\, Informa Healthcare.
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
This 3-hr virtual seminar will take a deeper look at your recruiting practice and review the objective for affirmative action as it relates to this function in terms of ensuring compliance. The session also features a discussion about how to make the most of your recruiting technology so that you are prepared to meet the OFCCP’s recently heightened enforcement efforts.
Why Should You Attend\:
Over the last 6 years\, we seen the OFCCP become better funded\, more sophisticated\, and more motivated than ever to enforce affirmative action rules. Further\, the changes initiated by the OFCCP have presented the greatest challenges for contractors with respect to compliance. In this new enforcement environment\, government contractors are well advised to be prepared for more audits and more settlements\, as there will be an aggressive increase in the OFCCP’s affirmative action enforcement efforts. From a risk perspective\, your recruiting practices pose the greatest legal liability for your organization.
In this 3-hr training\, we’ll take a practical look at what you should be doing now from a recruiting perspective to get and stay in compliance with the directives of a newly attentive OFCCP.
Learning Objectives\:
Attendees will learn
How do you respond to ADHD when medication isn’t an option? Explore complementary and alternative methods (CAM) for treating ADHD symptoms and learn what techniques may or may not provide the best outcomes for your patient.
Full Description\:
In 2003\, the Centers for Disease Control and Prevention found that 56.3% of the children with ADHD in the U.S. were using medication to treat their disorder. What about the other 44%? Despite evidence that 80-96% of children with ADHD
respond to stimulant medication treatment\, many parents and guardians elect not to treat their children this way due to fears of side-effects\, concerns about drug abuse later on in life\, religious convictions\, medical issues\, and/or future career limitations.
This webinar uses an objective\, evidence-based approach to discuss what treatment options are available when medication is not an option. Discover scientific research on complementary and alternative medicine (CAM) techniques and help determine the best treatment for your client.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
• Discuss evidence-based\, complementary and alternative medicine (CAM) and why parents may not elect to medicate children diagnosed with ADHD
• Explore well designed\, replicated double-blind research on effective CAM techniques
• Determine if a CAM technique is working and recognize those that are NOT shown to be effective in treating ADHD
• Design a scientifically investigated treatment plan for ADHD that does not include medication
• Explain why medication for ADHD is beneficial and can be combined with CAM techniques as part of an effective treatment strategy
Your Presenter\:
KEVIN T. BLAKE\, PhD\, P.L.C.\, is a licensed psychologist and author with over 20 years of experience as a nationally recognized authority on learning disorders and ADHD in children\, adolescents\, and adults. This interest spurred from his own struggles overcoming a reading disorder/dyslexia and hearing impairment.
Dr. Blake serves as a member of the American Psychological Association\, International Dyslexia Association\, Children and Adults with Attention Deficit Disorders\, Learning Disabilities Association\, and the National Attention Deficit Disorder Association and was a 1991 delegate to the National Institute for Literacy’s “LEAD 2000 Congress\,” where he advised Congress on diagnostic and remediation issues.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\:
https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Psychologists\, Social Workers\, Licensed Professional Counselors\, Marriage and Family Therapists\, School Psychologists\, Guidance Counselors\, Psychiatric Nurses\, Nurses\, Psychiatric Nurse Practitioners\, Case Managers\, Alcoholism and Drug Abuse Counselors/Addiction Professionals\, Pharmacists\, Physicians\, Psychiatrists\, Mental Health Administrators\, Special Education Teachers\, College Counselors\, Clergy\, School Administrators
Leading real estate consultant Christina Suter\, owner of Ground Level Consulting in Pasadena\, CA\, co-hosts a FREE one-hour educational webinar with MOR Financial at 1\:00PM Pacific Time on May 24. She will discuss the current domestic and global economy\, how it affects real estate portfolios\, what investments make sense at this time\, and when to buy. Sean Morsi and Ajay Mehra of MOR Financial will address asset-based lending\, notes and trust deeds for real estate cash flow without direct property ownership.
Topics include\:
• Where the US and International economy is now.
• Are we still in a recession?
• Why should we care as real estate investors?
• How does this affect investment decisions?
• When is it a good time to buy?
• What should I be buying?
• Cash flow through real estate without owning a single property!
As the founder and lead consultant of Ground Level Consulting\, Christina Suter brings two decades of real-world experience as a serial small business owner and real estate investor. She developed her extensive financial and operational skills firsthand as she faced and overcame each difficulty that appeared along the way. As a result\, Christina has started up\, managed and sold several businesses successfully\, while developing an extensive real estate portfolio. Learn more at www.groundlevel-consulting.com
Specializing in trust deed investments\, MOR Financial helps investors generate passive monthly income using real estate without owning a single property. Join us on the webinar to learn more about notes\, trust deeds and how to protect your assets. To learn more about MOR\, please visit www.mor-capital.com | www.morfinancial.com
Please note\: Correct time is at 1\:00PM in the afternoon PDT (site glitch stuck on AM).
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120524T180000Z DTEND;VALUE=DATE-TIME:20120524T180000Z UID:http://www.webinarcentral.net/content/free-webinar-developing-student-success-through-college-readiness URL;VALUE=URI:http://www.webinarcentral.net/content/free-webinar-developing-student-success-through-college-readiness SUMMARY:Free Webinar\: Developing Student Success Through College Readiness DESCRIPTION:The Learning House\, Inc.\, an online education solutions partner that helps colleges and universities develop and grow high-quality online degree programs and courses\, will host a free webinar titled “Developing Student Success Through College Readiness” on Thursday\, May 24\, at 1 p.m. EDT.
During the webinar\, Victoria Alexander\, Vice President of Curriculum Development\, and Elizabeth Dalton\, Manager of Digital Curriculum\, will outline several variables to consider when designing a developmental education program\, including\:
• Financial aid eligibility
• Course credit availability
• Timing of courses (parallel vs. front-end)
• Student support requirements
• Cost containment
• Curriculum design
The webinar will also discuss using technology and online developmental education classes to enable student success.
To register for the webinar\, please visit\: http\://www.learninghouse.com/resources/webinars/developing-student-success
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120529T180000Z DTEND;VALUE=DATE-TIME:20120529T180000Z UID:http://www.webinarcentral.net/content/tips-and-tricks-stay-out-spam-folder URL;VALUE=URI:http://www.webinarcentral.net/content/tips-and-tricks-stay-out-spam-folder SUMMARY:Tips and Tricks to Stay Out of the Spam Folder DESCRIPTION:Staying out of the spam folder is tougher than you might think. Over 20% of legitimate email never makes it to the inbox. Customers quickly become frustrated when they don’t receive important messages like password resets\, purchase confirmations and shipping notifications. Join email experts Carly Brantz and Elmer Thomas on May 29th at 1\:00 PM EDT as they break down ways to make sure your email stays out of the spam folder.
This webinar will cover\:
•CAN-SPAM Act Compliance
•Spam trigger words
•Importance of text-only versions
•How to authenticate your email
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120530T160000Z DTEND;VALUE=DATE-TIME:20120530T173000Z UID:http://www.webinarcentral.net/content/hipaa-breach-notification-webinar-complianceonline URL;VALUE=URI:http://www.webinarcentral.net/content/hipaa-breach-notification-webinar-complianceonline SUMMARY:HIPAA Breach Notification - Webinar By ComplianceOnline DESCRIPTION:This 90-minute webinar on HIPAA Breach Notification will show how to create an effective breach notification policy for your organization and how to follow through when a breach occurs. You will learn about the kinds of threats that exist for PHI\, information security methods you can use to keep breaches from happening\, and be in compliance with the HIPAA Security Rule as well.
Why Should You Attend\:
The HIPAA Breach Notification Rule has been in effect since September 23\, 2009 and most organizations are not prepared to respond to a breach of PHI and report and document it properly. We will discuss the origins of the rule and how it works\, including interactions with other HIPAA rules and penalties for violations.
The presentation will cover what goes into an effective breach notification policy\, how to prevent breaches as much as reasonably possible and what steps to take when a security incident or breach has occurred. We will cover the essentials of information security methods you can use to keep breaches from happening\, and be in compliance with the HIPAA Security Rule as well. We'll also discuss the new penalties for non compliance\, including mandatory penalties for \\"willful neglect\\" that begin at $10\,000.
Learning Objectives\:
Many sponsors and CROs rely on an IT infrastructure that includes multiple disconnected safety and pharmacovigilance systems that vary by region and vendor. Although merging these systems into a single global solution may seem daunting and provide you with many technical challenges\, it could be a crucial goal on the horizon for your organization.
Please join BioPharm Systems' Dr. Rodney Lemery\, vice president of safety and pharmacovigilance\, for this free one-hour webinar in which he will review a recent project for a top pharmaceutical company that entailed the merging of multiple drug safety systems into one global Argus Safety pharmacovigilance system.
Specific topics that will be examined include\:
-Adverse Event Case Migration
-Merging and Configuring
-Data Cleansing and Consistency
-Configuring Reporting Rules
Wednesday\, May 30\, 2012 @\:
7\:00 a.m. US Pacific time
8\:00 a.m. US Mountain time
9\:00 a.m. US Central time
10\:00 a.m. US Eastern time
15\:00 UK time
16\:00 Central European time
This 21 CFR Part 11 training will analyze the regulations and provides concrete guidance on compliance for Electronic Medical Records.
Description\:
Electronic Medical Records are the future. Some facilities and doctors are already using this cutting edge technology\, and the medical community in general is moving in this direction.
FDA regulations governing electronic records and electronic signatures will be enforced upon these systems as they are used and become more prevalent. This presentation analyzes the regulations and provides concrete guidance on compliance.
Areas Covered in the seminar\:
Did you know that hosted desktops\, or desktops-as-a-service (DaaS)\, will be the biggest and most interesting opportunity for enterprises rethinking their desktop deployments with virtualization? It´s about reducing cost and improving scalability\, control and service!
Our experts will explain you the benefits of Virtual Desktops and you will learn how you can chart the right course for your organization - from Infrastructure-as-a-Service (IaaS) to VDI and Desktop-as-a-Service.
Register now and get ready to interact with Latisys!
We look forward to seeing you online and hope you enjoy our Webinar(s)!
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120531T160000Z DTEND;VALUE=DATE-TIME:20120531T170000Z UID:http://www.webinarcentral.net/content/how-sell-your-idea URL;VALUE=URI:http://www.webinarcentral.net/content/how-sell-your-idea SUMMARY:How to Sell Your Idea DESCRIPTION:Price Associates is once again excited to host a complimentary webinar featuring Justin Foster\, Brand Strategist and www.SlideKlowd.com co-founder. Justin will be speaking on the 5 \\"must haves\\" for selling your idea.
Whether you are a start-up selling your idea to VCs or are an established brand introducing a new product / service to the marketplace\, you will learn\:
~ 3 reasons why ideas die
~ How demographic data can be misleading
~ Why doctors get paid more than janitors
~ How the future of your idea may depend on a 10-second span
~ Why pictures and words are rocket fuel for ideas
This webinar is open to anyone who's livelihood depends on the ability to sell an idea\: Executives\, business owners\, consultants\, and marketing and sales teams. Feel free to share the webinar link with anyone that you think would benefit from attending.
Title\: How to Sell Your Idea
Date\: Thursday\, May 31\, 2012
Time\: 9\:00 AM - 10\:00 AM MDT
Reserve your Webinar seat now at\:
https\://www3.gotomeeting.com/register/324837894
This webinar on documentation and record keeping related to food safety will cover FDA requirements regarding establishment and maintenance of records related to food safety help you make sure you fulfill the FDA's expectations.
Why Should You Attend\:
Food manufacturers\, processors\, packers\, distributors\, handlers\, transporters and importers need to become aware of and begin implementation of new food safety record keeping requirements. While the FDA may not have yet clearly stated and established food traceability requirements\, they have clearly established record keeping and documentation requirements that allow them to require traceability of all food handling processes and transportation. By citing customs and border protection needs under homeland security needs\, the FDA is now empowered to require and inspect food handling and safety documentation for virtually all phases of food production. In order to prove that you are working to prevent food safety problems and outbreaks\, you had better have a sophisticated and well managed documentation system. Failure to do so can cost you $244 per hour in federal inspection costs and will cause shipments to stop in their tracks.
This webinar will cover what is required and will help you make sure you fulfill the FDA's expectations. We will discuss requirements that the FDA might establish regarding establishment and maintenance of records by persons (excluding farms and restaurants) who manufacture\, process\, pack\, transport\, distribute\, receive\, hold\, or import food. The records that are required to be kept by these regulations are those needed by FDA for inspection to allow FDA to identify the immediate previous sources and immediate subsequent recipients of food.
Areas Covered in the Seminar\:
This webinar on clinical trial audit/ inspection preparedness will discuss in detail about applicable regulatory and sponsor requirements\, guidelines and SOPs\, and how you can ensure that the conduct of clinical research at the investigative site(s) complies with them.
Why Should You Attend\:
Significant audit/inspection findings expose you and your organization to regulatory or contractual sanctions\, including but not limited to – discontinuation\, disqualification\, seizure\, injunction and/or civil money penalties.
Your position\, as a clinical research professional\, has an important role in your organization’s preparation for and success at audits/inspections\, and it is your responsibility to know how to ensure your organization’s readiness for an audit/inspection at all times.
This training will teach you how to prepare for an audit or inspection and how to act and respond to questions during the audit or inspection. We will discuss in detail about applicable regulatory and sponsor requirements\, guidelines and SOPs\, and how to ensure the conduct of the clinical research at the investigative site(s) complies with them. By attending this training you will be able to appropriately act upon the audit or inspection findings – to correct current misconduct and prevent future recurrence.
Learning Objectives\:
Why Should You Attend\:
In this Webinar\, the application of the terms GLP and GMP will be explored\, as there is often confusion in their application during development. This presentation will define the terms and their application in the development environment.
During product development within an organization that has yet to commercialize a product\, the use of the terms GLP and GMP are often confused and may be used incorrectly. Doing so can result in reducing credibility by regulatory health authorities\, as well as cause confusion when working with collaborators. The objective of this seminar is to define the terms\, what they mean and how they are applied.
Areas Covered in the Seminar\:
This 4-hr virtual session on social media policies will help you navigate the complexity of how to develop a social media policy that is in compliance with your Legal\, Compliance\, and HR Department.
Why Should You Attend\:
This workshop will teach you the protocol for engagement on each social network\, namely\, Facebook\, Twitter\, Google+\, and Pinterest. At the end of this workshop you will be able to develop guidelines for employee usage\, and learn how to leverage social networks to increase your visibility among top candidates. You will also learn how to establish your company as an employer of choice. In addition\, you will learn how to engage\, and be successful on social networks. It all begins with a strong\, and efficacious social media policy.
This session discusses your reasons and rights as an employer to establish guidelines for social media usage for optical outcomes. It also educates HR Professionals on how to levy consequences that is in compliance with HR Law. We will cover case studies of employees who have been fired due to their negative social media behavior\, we will look at cases that were won in favor of the company\, and cases where employees have sued companies for being fired where the employee won.
Areas Covered in the Seminar\:
This training will provide a practical methodology for creating and applying Risk-Based Equipment Validation. It will show an example of how this process may be integrated into a facility Master Validation Plan.
Why Should You Attend\:
In installing equipment\, how much validation is enough? How much is too much? Risk-Based Validation establishes rules for what is appropriate and is the FDA-preferred method for determining what qualification protocols are required. It is based on the intended use of the equipment and the impact it may have on regulated processes\, safety and quality.
This presentation teaches a practical methodology for creating and applying Risk-Based Equipment Validation. It shows an example of how this process may be integrated into a facility Master Validation Plan. It includes a specific real-life project involving over 100 separate pieces of equipment and utilities\, and the regulatory inspector's subsequent comments.
This webinar will provide valuable assistance to all regulated companies that need to prepare for inspection of the facilities. We will discuss both laboratory instruments and critical facility systems. We will provide templates for risk assessment and validation strategy. A case study will illustrate the time lines\, cost savings and benefits of a risk-based validation master plan.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120531T160000Z DTEND;VALUE=DATE-TIME:20120531T170000Z UID:http://www.webinarcentral.net/content/how-do-i-keep-fda-happy-my-contract-manufacturer-webinar-complianceonline URL;VALUE=URI:http://www.webinarcentral.net/content/how-do-i-keep-fda-happy-my-contract-manufacturer-webinar-complianceonline SUMMARY:How do I Keep FDA Happy with my Contract Manufacturer-Webinar By ComplianceOnline DESCRIPTION:This webinar will cover techniques and process that can help you assure reliability and consistent quality from your suppliers or contract manufacturers. You will learn how to monitor your supplier and ensure they meet FDA's quality requirements.
Why Should You Attend\:
No matter where a product is manufactured\, quality is the responsibility of the organization whose name appears on the label. If you hire a contract manufacturer to make products that will carry your label and your name\, the responsibility for the quality of that product is yours. There are many things that you can do to assure quality and these quality assurance procedures will be covered in this webinar. It should not be necessary to do all of the things that will be discussed - - the secret is to create a system that fits your products\, your contractor and your needs. In fact\, the quality assurance process may change over time as you learn more about the contract manufacturer you are using and the contractor's commitment to quality.
Areas Covered in the Seminar\:
This 90-minute webinar on device corrections and removals will clarify your obligations for corrections and removals under Part 806 of the FDA regulations.
Why Should You Attend\:
When your firm finds a problem with a device you shipped and fixes it\, do you report it to the FDA?
If you send a letter to a customer that says\, “We found a problem\, but\, not to worry\, we will fix it for you!”\, you may have invoked the Corrections and Removals process. Under Part 806 of the FDA regulations\, you must report this event to FDA. Under certain circumstances\, you may not need to report\, but you must keep a record of your decision.
An FDA Inspection will check for Corrections and Removals since it is part of QSIT. Often Inspectors will check specific actions\, since they will monitor your website and have copies of letters you sent to customers. If you send a letter that notifies your customers of a problem\, it will almost certainly get to a competitor who will send a copy to FDA. If you didn’t report to FDA\, the Inspector will ask for your records documenting the reason not to report. This webinar will clarify your obligations for corrections and Removal under Part 806.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120601T200000Z DTEND;VALUE=DATE-TIME:20120601T200000Z UID:http://www.webinarcentral.net/content/free-tech-webinar-7-myths-about-agile URL;VALUE=URI:http://www.webinarcentral.net/content/free-tech-webinar-7-myths-about-agile SUMMARY:Free Tech Webinar 7 Myths about Agile DESCRIPTION:Presented by Joseph Flahiff
Friday\, June 01\, 2012 - 12\:00 Noon to 01\:00 PM PST
Corp-Corp.com cordially invites you to join a Technology related webinar on title “7 Myths about Agile “
Webinar Highlights
Agile Expert\, Joseph Flahiff will help debunk 7 common myths about agile. As any idea becomes popular myths crop up everywhere. Joseph addresses these myths head on.
Myths we will cover include\:
• Agile is just for software projects
• Agile requires dedicated resources (People)
• There is no planning in agile
• You can’t have fixed requirements in agile
And many more. Come with your questions too because we will save time to address you specific burning questions about agile.
Speaker's Profile\:
Joseph Flahiff is the President and CEO of Whitewater Projects a firm that addresses the issues with agile in mixed agile/waterfall contexts commonly found in enterprise organizations and government. He is also Co-Chair of PMI-ACP Content Support team. Whitewater Projects provides numerous resources on their website including\: free monthly webinars\, PMI-ACP Sample exam\, Interviews with other agile experts and a list of upcoming classes worldwide.
Registration\:
To register for this webinar\, Visit http\://www.corp-corp.com/blog/myths-about-agile/?aid=web1wrc
There will be an opportunity to ask your questions and doubts at the end of the webinar. Register now and join with us. Feel free to forward this message to your friends and colleagues.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120601T200000Z DTEND;VALUE=DATE-TIME:20120601T200000Z UID:http://www.webinarcentral.net/content/understanding-inattentive-adhd-recent-updates-evidence-based-screening-and-treatment-strate-1 URL;VALUE=URI:http://www.webinarcentral.net/content/understanding-inattentive-adhd-recent-updates-evidence-based-screening-and-treatment-strate-1 SUMMARY:Understanding Inattentive ADHD\: Recent Updates in Evidence-Based Screening and Treatment Strategies DESCRIPTION:Discover why Inattentive ADHD is different from other types of ADHD and learn the latest information about screening\, SCT\, symptomatology\, comorbidities\, treatment modalities\, medication\, and how this disorder may be mentioned in DSM-5.
Full Description\:
Why is Inattentive ADHD Different? New Information
Attention-Deficit Hyperactivity Disorder\, Predominately Inattentive Type is NOT a “calmer” or “lighter” version of ADHD. The neurophysiology\, symptoms\, treatment methods\, and medications for this disorder are different than the other types of ADHD. Since patients with Inattentive ADHD are not typically as disruptive as those with other types of ADHD\, this type is commonly misunderstood or goes unrealized by the mental health professional. Little research has been done compared to Combined ADHD and most seminars and webinars only spend a small portion of time on Inattentive ADHD.
This one-hour course will provide participants with the latest information about screening\, Sluggish Cognitive Tempo (SCT)\, symptomatology\, comorbidities\, treatment modalities\, medication\, and how Inattentive ADHD may be mentioned in DSM-5.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Identify the differences between Attention-Deficit/Hyperactivity Disorder\, Predominately Inattentive Type (Inattentive ADHD)\, and other forms of ADHD
Define treatment methods for Inattentive ADHD and how such methods are different than those for other forms of ADHD
Outline the common co-morbidities of Inattentive ADHD
Evaluate new research about Sluggish Cognitive Tempo and its relationship to ADHD
Discuss how Inattentive ADHD may be described in DSM-5
Your Presenter\:
KEVIN T. BLAKE\, PhD\, P.L.C.\, is a licensed psychologist and author with over 20 years of experience as a nationally recognized authority on learning disorders and ADHD in children\, adolescents\, and adults. This interest spurred from his own struggles overcoming a reading disorder/dyslexia and hearing impairment.
Dr. Blake serves as a member of the American Psychological Association\, International Dyslexia Association\, Children and Adults with Attention Deficit Disorders\, Learning Disabilities Association\, and the National Attention Deficit Disorder Association and was a 1991 delegate to the National Institute for Literacy’s “LEAD 2000 Congress\,” where he advised Congress on diagnostic and remediation issues.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Psychologists\, Social Workers\, Licensed Professional Counselors\, Marriage and Family Therapists\, School Psychologists\, Guidance Counselors\, Psychiatric Nurses\, Nurses\, Psychiatric Nurse Practitioners\, Case Managers\, Alcoholism and Drug Abuse Counselors/Addiction Professionals\, Clergy\, School Administrators\, Physicians\, Psychiatrists\, Mental Health Administrators\, Special Education Teachers\, College Counselors
Corp-corp.com invites you for its upcoming webinar 7 Myths about Agile
Presented by\: Joseph Flahiff
Time\: 12\:00 Noon to 01\:00 PM PST
Date\: Friday\, June 01\, 2012
HOT Topics of this session\:
Agile Expert\, Joseph Flahiff will help debunk 7 common myths about agile. As any idea becomes popular myths crop up everywhere. Joseph addresses these myths head on.
• Agile is just for software projects
• Agile requires dedicated resources (People)
• There is no planning in agile
• You can’t have fixed requirements in agile
Overview\: Auditing analytical laboratories can be complex because of the preparation that is often required. All of the GMP rules do not apply to the laboratory\; while there may be additional requirements depending upon the type of testing that is being conducted.
In many cases\, the laboratory itself may not understand what regulations apply to the work that is being conducted. This presentation will discuss what advance preparation is needed on the part of the auditor\, and discuss what the auditor should look for during the audit. Since documentation is often an issue\, a discussion of documentation problems will be presented.
Areas Covered in the Session\:
GMP regulations that apply to analytical laboratories.
Reviewing documentation
Advance preparation for the audit
Auditing styles and structures
Equipment and laboratory instrument qualification.
What to look for while doing a walk-through.
Other regulations and standards\, including ISO 17025
Following through on the audit
Who Will Benefit\:This webinar will be of benefit to company auditors who need to investigate the qualifications of contract testing laboratories and internal testing facilities. It will also be beneficial to workers in laboratories that will be audited or inspected by external parties. Personnel from companies that perform testing on small molecule drugs\, biologicals\, and nutraceuticals will benefit from knowing what standards are being applied to them.
The following specific types of workers will benefit from this webinar\:
External and Internal Auditors
Supervisors and Analysts in Quality Control Laboratories and Quality Assurance groups.
Supervisors and Analysts in Contract Testing Laboratories
Personnel Responsible for Selecting Contract Testing Laboratories
Consultants
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: The Microbiology Lab must take leadership in contamination control support for production because it is the hub of the necessary technical expertise.
This broad manufacturing support role covers many areas\, including routine raw material and product testing\, disinfectant/sanitant qualification\, water and compressed gas testing\, environmental monitoring\, microbiological “awareness training” of production operators\, etc. Perhaps their most difficult leadership role is in contamination control investigations where product is at risk\, manufacturing may be at a standstill\, and the pressure to resume operation with a quick (and possibly incorrect) fix is tremendous. In these situations\, the microbiology lab can either gain or lose credibility in the eyes of manufacturing management depending on the timeliness of its success in discovering and resolving the problems. This presentation will discuss these roles and how the lab can assure these activities are performed in a manner that facilitates root cause excursion investigations and avoids the lab or its personnel becoming the inadvertent cause of the excursions.
Why Should You Attend\:
Someone must spearhead the effort to control a manufacturing site's microbial contamination issues. Though it typically is QA's responsibility to \\"assure\\" that production has no facility\, raw material\, or process contamination that could lead to product contamination\, QA is not typically staffed by microbiologists who truly understand all the issues with this aspect of quality assurance. Therefore\, it naturally should fall to the microbiology lab to take a lead role since likely no one else at the site has that expertise or is so intimately involved in the contamination assessment testing. Those supervising and doing this testing have a crucial role in the site's microbiological condition. They must be more than a data mill -- they must also interpret the data\, even when not asked to do so. In spite of the logical role the Micro Lab can serve in proactively controlling microbial contamination on-site\, there are often many impediments to their being able to assume this role. They are not insurmountable\, but they must be overcome for the Labs to be able to help. Don't miss this webinar if you want to better understand how the micro lab can be more effectively utilized to prevent or head off microbial contamination issues as well as effectively resolve such problems should they have already occurred.
Areas Covered in the Session\:
How contamination is controlled
Why the microbiology lab should lead in contamination control
Routine contamination evaluation activities
Microbiological training
Root cause and impact investigations
Impediments to leadership
Observed contamination correlations &\; doing the right thing
Who Will Benefit\: This webinar will be valuable for all companies that operate WFI or Purified Water systems\, particularly for those in FDA and EMEA regulated industries\, including Medical Devices\, Diagnostics\, Pharmaceuticals\, and Biologics fields\, as well as consumer products and cosmetics companies. The employees who will benefit include\:
QA managers and personnel involved in investigations of excursions and preparing CAPAs
QC managers and personnel involved in sampling\, testing\, and trending chem and micro data from water systems
Utility operators and their managers involved in maintaining and sanitizing water systems
Validation managers and personnel
QA managers and Regulatory Affairs personnel involved in defending water system operations and quality data to FDA and EMEA inspectors and outside auditors
Consultants and Troubleshooters
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
This ICH Q10 training /webinar will discuss the evolution and interpretation of the pharmaceutical GMPs as a quality control regulation to the Quality Assurance emphasis of the Pharmaceutical Quality System as defined in ICH Q10.
Why should you Attend\:
Since the release of the Quality System Regulation for medical devices\, the FDA has been trying to transition the pharmaceutical industry to a Quality System approach to compliance. The issuance of the Guidance for the Industry\: Quality System Approach to Pharmaceutical CGMPS and ICH Q10. Pharmaceutical Quality System has brought new focus to Quality Systems in the pharmaceutical industry. This seminar will discuss the transition in the FDA oversight from a strict audit against the regulations as defined in the GMPs to a review of the high level quality system and the involvement of senior management in compliance to the GMPs.
The discussion will begin with the establishment of ICH and its original purpose to facilitate registrations throughout the world and discuss the impact of Quality systems such as ISO 9000 and the medical device GMPs. It will continue with the effort of the agency to change the way it regulates and the impact of the international focus on Quality Systems and how ICH broadened its scope and responded to the international move to a quality systems approach.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120605T093000Z DTEND;VALUE=DATE-TIME:20120605T103000Z UID:http://www.webinarcentral.net/content/la-qualit%C3%A9-de-donn%C3%A9es-au-service-de-la-business-intelligence URL;VALUE=URI:http://www.webinarcentral.net/content/la-qualit%C3%A9-de-donn%C3%A9es-au-service-de-la-business-intelligence SUMMARY:La qualité de données au service de la business intelligence DESCRIPTION:Ce webinar d’une heure présenté par Talend et Jaspersoft vous présentera \:
- pourquoi la gestion de données joue un rôle essentiel dans la business intelligence \;
- comment surveiller et contrôler la qualité de ses données dans un environnement en constant changement \;
- les outils peu coûteux permettant de profiler\, surveiller et nettoyer les données \;
- comment définir votre stratégie de gestion de données actuelle et future.
Date \: 5 juin 2012 de 10h30 à 11h30
Inscrivez-vous dès maintenant \: http\://nxy.in/5qxki
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120605T200000Z DTEND;VALUE=DATE-TIME:20120605T200000Z UID:http://www.webinarcentral.net/content/childhood-peer-aggression-and-victimization-1 URL;VALUE=URI:http://www.webinarcentral.net/content/childhood-peer-aggression-and-victimization-1 SUMMARY:Childhood Peer Aggression and Victimization DESCRIPTION:This one-hour webinar will introduce attendees to the interpersonal dynamics of childhood peer aggression and interventions for victims and aggressors. Current research on treatment and prevention will also be discussed.
Full Description\:
The Interpersonal Dynamics of Bullying
This webinar will provide an understanding of the interpersonal dynamics of childhood peer aggression\, also referred to as bullying. Understanding the fundamental elements of this unique relationship will help attendees distinguish bullying from usual peer conflicts. The short and long-term effects of victimization will be reviewed including the “bully victim” who often normalizes antisocial behavior. We will discuss interventions for victims and aggressors and cover recent research suggesting that structural family therapy and solution-focused family therapy are effective at reducing the abusive behavior of aggressors as well as assisting victims. In cases where family therapy is not an option\, viable alternatives (individual and group cognitive therapy) are also reviewed. Additionally\, recent research on prevention will be included.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Discuss the unique interpersonal dynamics of childhood peer aggression and victimization
Define the personality and behavioral traits of children who are aggressive toward peers
Assess the impact of childhood peer aggression on the victim
Discuss basic theory and practice of structural family therapy\, solution-focused family therapy\, and cognitive therapy for aggressors and victims
Examine the results of the research on effective prevention of childhood peer aggression
Your Presenter\:
THOM MOTE\, M.Ed.\, LPC\, is a privately practicing counselor in Northwest Georgia and Chattanooga\, Tennessee. His 16 years of counseling experience include specializing in adjustment therapy\, life transitions\, and grief counseling with individuals\, couples\, and families. He has presented numerous workshops to live and television audiences on topics such as abusive youth\, structured parenting\, positive psychology\, and compassion fatigue.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Social Workers\, Psychologists\, Counselors\, Play Therapists\, Juvenile Justice Personnel\, Nurses\, Psychiatric Nurses\, Nurse Practitioners\, Educators\, Marriage and Family Therapists\, Alcohol and Drug Abuse Counselors\,Parents
Overview\: The FDA's Quality System Regulation (QSR) prescribes the Quality Management System for a medical device manufacturer who markets in the US.
ISO 13485 covers the rest of the world. The webinar describes management responsibility by reviewing the regulations and the reasoning that FDA published. Management responsibility\, in QSR\, has five major components\: Quality Policy\, Organization\, Management Review\, Quality Planning\, and Quality System Procedures. The webinar covers each of these topics and provides a list of things you should consider in your implementation.
Why should you attend\: One of the most common areas for FDA Warning Letters is Management Responsibility. FDA considers this a principle subsystem and is where they start inspections. Ensuring that you understand what they expect and how to implement it is a valuable approach to preventing problems. More than that\, however\, a company can achieve tremendous value by setting up the FDA system. Effective management reviews\, for example\, can help your company identify opportunities for improvement\, resolve issues\, and make better products at lower cost. Quality plans and document structure outlines can help ensure you have covered all the requirements\, i.e.\, no gaps\, but that you haven’t duplicated effort or created redundant procedures.
Areas Covered in the Session\:
Valuable documents that provide understanding
Quality System Regulation (QSR)\, including the definitions
QSR Preamble
ISO 13485\:2003
FDA's Quality System Inspection Technique (QSIT) manual
Warning Letters
Subject Areas covered
Quality policy
Organization
Responsibility and authority
Resources
Management Representative
Management review
Quality planning
Quality system procedures
For each subject area\, the webinar includes information from the valuable documents listed above
Who will benefit\:
Device Company Executives
Device company Managers
Quality Managers
Regulatory Affairs Managers
Risk Managers
Management Representatives
Production Managers
Design Engineering Managers
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: This webinar is not a project management certification course. It is designed to provide the tools necessary to assist those designing a result or deliverable to achieve that end. It will provide valuable guidance to regulated companies in development and implementation of Project Management Planning and Techniques for new product development\, regulatory compliance audit responses\, proof of \\"progress against plan\\"\, and other activities requiring a planned documented rationale.
Three of the most common tools will be discussed. Common variants such as \\"dashboards\\" will also be presented. A very simple approach using common Excel- or Word-type PC applications programs that can be used immediately will be highlighted. Regular use of a few simple but powerful tools will virtually eliminate \\"fire fighting\\" in a new project. Regular use can contribute greatly to reduction of scheduling uncertainty\, incomplete projects when time is running out\, increased product liability\, assist in company-wide cost reduction efforts\, with less chance of recalls\, and an improved bottom line.
Why you should attend\: The FDA expects companies to manage projects formally - to include regulatory requirements\, design and/or change control\, with consideration of all applicable standards. The EU MDD and their notified bodies are no different. How can this be done from a project's inception? How can a Project Leader or Project Manager ensure critical elements are not omitted until late in the project when disaster looms? How to minimize scope creep? What are the \\"lean\\" and \\"Agile\\" benefits and shortcomings in the cGMP environment? What is \\"failing fast\\" in the \\"build-measure-learn\, re-evaluate / decide loop? How to gain management support for the Milestones\, Tasks\, and Timelines? Use the Plan as a powerful tool with FDA auditors. Use variations on these tools for any project\, from the smallest to major company projects. These techniques are not rocket-science\, but require the implementation of formal methods with documented and defensible rationale. Use these tools to bring predictability to your company's product development process. Use them to defend your remediation efforts with the FDA. Use them to prove \\"progress against plan\\".
Areas Covered In the Session\:
Formal Project Management to Fulfill Common cGMP Requirements
\\"Failing Fast\\" Lean Project Management
The Three Most Common PM Tools -- Gantt\, CPM\, PERT + others
Work breakdown Structure\, Milestones\, Tasks
Drive Success for Failure Fast
The Build\, Measure\, Learn\, Re-evaluate Loop
A Template / Example
One Major\, But Often Neglected\, Use
Who will benefit\:
Senior Management in Drugs\, Devices\, Biologics\, Dietary Supplements
QA
RA
R&\;D
Engineering
Production
Operations
Consultants\; others tasked with project leadership responsibilities
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: This webinar is not a project management certification course. It is designed to provide the tools necessary to assist those designing a result or deliverable to achieve that end. It will provide valuable guidance to regulated companies in development and implementation of Project Management Planning and Techniques for new product development\, regulatory compliance audit responses\, proof of \\"progress against plan\\"\, and other activities requiring a planned documented rationale.
Three of the most common tools will be discussed. Common variants such as \\"dashboards\\" will also be presented. A very simple approach using common Excel- or Word-type PC applications programs that can be used immediately will be highlighted. Regular use of a few simple but powerful tools will virtually eliminate \\"fire fighting\\" in a new project. Regular use can contribute greatly to reduction of scheduling uncertainty\, incomplete projects when time is running out\, increased product liability\, assist in company-wide cost reduction efforts\, with less chance of recalls\, and an improved bottom line.
Why you should attend\: The FDA expects companies to manage projects formally - to include regulatory requirements\, design and/or change control\, with consideration of all applicable standards. The EU MDD and their notified bodies are no different. How can this be done from a project's inception? How can a Project Leader or Project Manager ensure critical elements are not omitted until late in the project when disaster looms? How to minimize scope creep? What are the \\"lean\\" and \\"Agile\\" benefits and shortcomings in the cGMP environment? What is \\"failing fast\\" in the \\"build-measure-learn\, re-evaluate / decide loop? How to gain management support for the Milestones\, Tasks\, and Timelines? Use the Plan as a powerful tool with FDA auditors. Use variations on these tools for any project\, from the smallest to major company projects. These techniques are not rocket-science\, but require the implementation of formal methods with documented and defensible rationale. Use these tools to bring predictability to your company's product development process. Use them to defend your remediation efforts with the FDA. Use them to prove \\"progress against plan\\".
Areas Covered In the Session\:
Formal Project Management to Fulfill Common cGMP Requirements
\\"Failing Fast\\" Lean Project Management
The Three Most Common PM Tools -- Gantt\, CPM\, PERT + others
Work breakdown Structure\, Milestones\, Tasks
Drive Success for Failure Fast
The Build\, Measure\, Learn\, Re-evaluate Loop
A Template / Example
One Major\, But Often Neglected\, Use
Who will benefit\:
Senior Management in Drugs\, Devices\, Biologics\, Dietary Supplements
QA
RA
R&\;D
Engineering
Production
Operations
Consultants\; others tasked with project leadership responsibilities
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Discover multiple classes of antidepressants and how they are used inside and outside of treating depression.
Full Description\:
This one hour webinar will introduce participants to the various classes of antidepressant drugs\, arranged according to the dates of their introduction into medicine. General uses\, side effects\, effects in pregnancy\, and uses outside of treating depression will be emphasized within each category. Having knowledge of the side effects will allow the non- prescriber to monitor for adverse effects that may limit a patient's daily functioning. We will also discuss withdrawal and overdose syndromes where applicable. Finally\, we will explore the STAR-D study results to attain a detailed description of the efficacy of these drugs to relieve depression.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Discuss the uses of antidepressants as antidepressants\, anxiolytics\, and analgesics
Identify the mechanisms through which these drugs relieve depression\, including references for further self-study
Examine the limitations of tricyclic antidepressants and the side effects to watch for in clinical practice
Discover what SSRI means\, the different serotonin receptors\, and common side effects of use as well as withdrawal distress (including serotonin withdrawal syndrome in the neonate)
Understand why dopaminergic agonist antidepressants can cause\, rather than relieve\, anxiety
Your Presenter\:
Robert M. Julien\, MD\, PhD\, is both an anesthesiologist and psychopharmacologist with over 40 years of experience. He received his PhD from the University of Washington in 1970 and his MD from the University of California at Irvine in 1977. Previously an Associate Professor of Pharmacology and Anesthesiology at the Oregon Health Sciences University\, Dr. Julien lectures widely on psychopharmacology. With over 36 years of continuous publication\, Dr. Julien's psychopharmacology textbook\, A Primer of Drug Action (Worth Publishers)\, is regarded as the definitive textbook of psychopharmacology\, covering both psychotherapeutic agents as well as substances of abuse. Dr. Julien is a nationally recognized speaker and expert in psychopharmacology.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Pharmacists\, Psychologists\, Social Workers\, Counselors\, Drug and Alcohol Counselors\, Marriage and Family Therapists\, Case Managers\, Nurse Practitioners
Understand the steps of a extractables / leachables study\, get knowledge about the gap analysis of literature sources and how to design an efficient E/L study.
Why Should You Attend\:
The FDA industry guidance for container-closure systems for packaging human drugs and biologics requires the testing of container closure components for extractable leachable for all injectibles. Since biologics products are particularly sensitive to leachable there has been increased scrutiny of extractable and leachable associated with biotechnology drug products. The time and resources required for testing for extractable/leachable can be conserved by appropriately planning the study.
This interactive webinar will provide an overview of the steps in a typical Extractables/Leachables study. The literature sources which can preliminary information essential for the plan of a E/L study will be discussed. Gap analysis of such literature leading to the design of an efficient E/L study will be addressed. Steps in an E/L study\, handling the data and cases studies will be presented.
Areas Covered in the Seminar\:
This webinar will help you understand how non-IND clinical trials at non-US locations can be used successfully to support an IND/IDE or a marketing approval application. It will cover the critical product specific issues (drugs\, biologics\, diagnostic kits and medical devices) that need to be addressed when using non-US data for discussions with FDA.
Description \:
FDA acceptance criteria for non-IND/IDE clinical trials are based on internationally recognized standards of quality\, ethics\, and practices for human subject protection. An adequately designed non-US study can be used to greatly reduce the time of cost of getting the tested product to the US market.
If you have conducted non-IND clinical trials at non-US locations or if you would like to understand how non-IND trials can be used successfully to support an IND/IDE or a marketing approval application\, this seminar is a must for you. The speaker will share his extensive experience in multi-national IND and non-IND studies to underscore the critical issues that need to be addressed when using non-US data for discussions with FDA. Case studies from drugs\, biologics\, diagnostic kits and medical devices will be used to highlight product specific issues with non-US clinical trials.
Areas Covered\:
Course Description\:
This 2-day on-site Course will help you gain a comprehensive understanding of the Regulatory Structure\, Clinical Trial Requirements and the Conduct of Running Clinical Research in Japan and South Korea. It will prepare you for the regulatory approval processes\, Agency meetings\, the complexities of running studies in both countries\, the importance of partner selection and the cultural knowledge needed for success. The recent changes made by PMDA and KFDA to be more sponsor-friendly will be reviewed. Real world experiences on actual interactions with the Agencies since these changes\, will also be discussed.
Who will Benefit\:
This course will be beneficial to the following personnel whose responsibilities require knowledge of Japan and South Korea's regulatory requirements for Life Science products\:
Overview\: This CAPA training program helps you to understand\, in 10 easy steps\, the entire CAPA process. It includes elements of Quality Tools\, Team Effectiveness\, Awards &\; Recognitions\, and Verification &\; Validation of actions taken. Attend this webinar to grasp the A to Z of CAPA and learn how to implement &\; manage it for success.
Why Should You Attend\: We have found out\, through auditing many organizations world-wide that the organizations are pretty good when it comes to corrective actions yet they are not nearly as good when it comes to the preventive actions. This webinar should provide you with enough ideas\, suggestions and HOW TOs that you and your teams and organization overall get much better on the preventive actions and even better on the corrective actions. Includes all elements of CAPA process step as required by ISO and regulatory agencies.
In addition\, it is represented in a practical and proven manner which can be immediately applied in your organization.
Areas Covered in the Seminar\:
Module 1
Introduction and Overview
Correction vs. Corrective Action
Understanding of all elements of CAPA process step as required by ISO and regulatory agencies
Introduction to CAPA elements in a practical and proven manner which can be immediately applied in your organization
Supporting stories and practical examples of CAPA - when each is appropriate and when one or the other is not appropriate
The regulations and international requirements for CAPA and the clear understanding how to suit your procedures\, work instructions and forms to address it
Module 2
Examples of problem solving tools\, management tools and measurement tools\, which are great for identification of the true root cause(s) of the issue
These tools also used for corrective actions\, for most optimal definition of the improvement\, for preventive actions
Visual representation of the tools and examples where and when to use them
Importance of proper assignment of a CAPA
Examples are provided when it might be a good thing to assign a CAPA to a team
Examples when would be a good thing to assign a CAPA to an individual
Examples and definitions of teams and team members roles and responsibilities
It can be used and applied in other areas inside and/or outside the organization when and where team work is required and expected
This section by itself can be taken out and applied to other processes and practices within or outside of the organization with the goal of continuous improvement
Module 3
Emphasize the importance and need of completing the verifications and/or validations of the actions taken to ensure that the issue has been resolved and the true root cause of the issue has been removed
Real-life examples and suggestions which can be used immediately after completing the webinar
Module 4
Examples how to appropriately award and recognize teams and individuals for producing the results
Additional references and pointers where more successful examples and instructions can be found so that you and your organization can benefit and profit more from the CAPA process and CAPA teams - and maybe more importantly have those outside the quality department more engaged and interested in participating in CAPA and continuous improvements
Q &\; A
Who Will Benefit\:
Quality Managers
Quality Engineers
Small business owners
CAPA investigators
Inspectors
Six Sigma specialists
Consultants
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
This Clinical Laboratory Improvement Amendments (CLIA) training will be valuable to CLIA regulated non-waived laboratories that run automated analyzers or semi-quantitative kit tests.
Why Should You Attend\:
All non-waived laboratories must have a QC and QA plan that meets CLIAs’s regulations. CLIA (Clinical Laboratory Improvement Amendments) has updated its requirements for QC and QA. CLIA has replaced the term Quality Assurance with the term Quality Assessment. The new guidelines regarding QA specifically stress measuring quality through all aspects of the testing process. This includes pre-analytical\, analytical\, and post-analytical parts of the process as a whole. QA is now focused on measuring outcomes and developing actions based on findings. The Quality Control process has guidelines in place for all three levels of testing\; Waived\, Moderately Complex and High Complexity.
Attend this webinar to understand the differences and the proper methods to meet the guidelines. It is important to understand that measuring quality is essential to assessing quality. The measurement of processes and the outcomes is the only way to truly assess quality.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120607T200000Z DTEND;VALUE=DATE-TIME:20120607T200000Z UID:http://www.webinarcentral.net/content/integrating-art-therapy-your-professional-practice-3 URL;VALUE=URI:http://www.webinarcentral.net/content/integrating-art-therapy-your-professional-practice-3 SUMMARY:Integrating Art Therapy into Your Professional Practice DESCRIPTION:This one-hour webinar provides attendees with a definition of art therapy\, its benefits\, &\; how it differs from verbal therapy. Case studies will
be presented to assist attendees in identifying indicators &\; key images in their clients’ art.
Full Description\:
This webinar program provides definitions of what Art Therapy is and how it differs from verbal therapy. The role of art-making in diagnosis and
treatment is addressed through assessment by examining age-appropriate drawing skills and the symbolism of images that have personal meaning to
our clients. In addition\, this course examines art-making as personal growth and its therapeutic benefits. The attendees will learn specific
indicators to look for in their clients’ art work and how to identify key images through the presentation of several case studies. Through these
case studies the participants will identify how clients can express their mood through drawing and painting. Psychological and behavioral
problems\, such as regression and impairments\, will be identified through the symbolism in clients’ art work.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
1.Discover a new method of communicating with clients
2.Examine effective Art Therapy techniques
3.Understand the therapeutic power that art provides
4.Acquire skills for assessing the client’s stress level
5.Discuss current research as it relates to Art Therapy and its effectiveness with clients
Your Presenter\:
Pamela M. Hayes\, MFT\, LMHC\, ATR-BC\, is an artist and a registered and board certified Art Therapist. She is licensed as a Marriage and Family
Therapist and Mental Health Counselor and is currently in private practice in Los Angeles\, California. Ms. Hayes developed the art therapy
program at the Rhode Island School of Design. For the past 15 years\, Ms. Hayes has worked in numerous psychiatric settings. Currently\, her focus
includes families\, couples\, adults\, and children struggling with mood and anxiety disorders\, addiction\, eating disorders\, abuse\, and grief-
related issues. Ms. Hayes has an undergraduate degree in Fine Arts from Parsons School of Design in New York City and a graduate degree in
Marriage and Family Therapy and Art Therapy from Notre Dame de Namur University in Belmont\, California. For more information about Ms. Hayes\,
please visit her website at\: www.hayesarttherapy.com
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to
attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound
quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save
time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Marriage and Family Therapists\, Licensed Professional Counselors\, Social Workers\, Psychiatric Nurses\, Drug and Alcohol Abuse Counselors\,
Pediatricians\, Physicians\, Art Therapists\, Pastoral Counselors\, Guidance Counselors\, Youth Pastors\, Youth Counselors\, Educators
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120608T160000Z DTEND;VALUE=DATE-TIME:20120608T170000Z UID:http://www.webinarcentral.net/content/eliminate-confusion-%E2%80%93-analytical-method-qualification-and-validation-webinar-complianceonlin URL;VALUE=URI:http://www.webinarcentral.net/content/eliminate-confusion-%E2%80%93-analytical-method-qualification-and-validation-webinar-complianceonlin SUMMARY:Eliminate the Confusion – Analytical Method Qualification and Validation - Webinar By ComplianceOnline DESCRIPTION:This webinar will help you understand the significant differences between qualification and validation of an analytical method\, the expectations and requirements of each\, and their place in the analytical method lifecycle.
Why Should You Attend\:
Execution of a method validation is a resource intensive activity\, both in terms of manpower\, equipment usage\, time\, and money. The more the process is well defined and understood\, the greater the potential for an efficient project. The less the process and its elements are understood\, the greater the chance for delays and additional resource expenditures. There is confusion and a lack of guidance over what constitutes a method qualification compared to a method validation\, and what are the requirements for different phases of validation\, what is needed at each product phase (I\,III\,commercial)\, and what to do when there are failures within a validation. Inclusion of a CRO as an additional factor in this plan potentially escalates areas that need resolution-differences in quality systems\, validation requirements\, and reports to name a few. Communication without common definitions and understanding of the terms can lead to areas of confusion\, project misdirection\, and missed timelines.
Learning Objectives\:
This training will enable the user to understand what is the difference in these terms - qualification and validation\, how each term applies to the group of methods for which the user is responsible\, and when each may be applicable. There are some essential elements of entry for a method for both qualification and validation- and these elements will be reviewed (development reports\, qualification reports\, ICH category defined for method…). In addition\, there can be excursions of various types in qualification/validation activities-and potential ways to address these will be covered.
Areas Covered in the Seminar\:
Untreated depression in children and adolescents can lead to more serious episodes of depression during adulthood. Drug choice and length of treatment can make a significant difference is the lives of your youngest patients.
Full Description\:
This one-hour webinar will introduce participants to the role of antidepressant drugs in treating depression in children and adolescents. During our time together\, we will examine drug efficacy both with and without adjunctive therapies\, including fluoxetine as the most effective medicine for this use. The issue of black box warnings and potential suicidality will be addressed as well as available alternative and adjunctive medications. Drug choice\, length of initial trials\, and withdrawal strategies will also be addressed. Finally\, we will discuss the TORDIA study. Its results will enable a detailed account of augmentation strategies when fluoxetine therapy is found to be insufficient.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Examine the unique use of fluoxetine therapy in child and adolescent depression as well as its limitations
Define the origins of early age depression and the mechanisms involved
Recognize that preschool depression is a real phenomenon and not a developmentally transient disorder
Discuss the later life consequences of untreated depression in children and early-age adolescents
Identify why adjunctive medication therapy may be needed for resistant depression
Your Presenter\:
Robert M. Julien\, MD\, PhD\, is both an anesthesiologist and psychopharmacologist with over 40 years of experience. He received his PhD from the University of Washington in 1970 and his MD from the University of California at Irvine in 1977. Previously an Associate Professor of Pharmacology and Anesthesiology at the Oregon Health Sciences University\, Dr. Julien lectures widely on psychopharmacology. With over 36 years of continuous publication\, Dr. Julien's psychopharmacology textbook\, A Primer of Drug Action (Worth Publishers)\, is regarded as the definitive textbook of psychopharmacology\, covering both psychotherapeutic agents as well as substances of abuse. Dr. Julien is a nationally recognized speaker and expert in psychopharmacology.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Pharmacists\, Psychologists\, Social Workers\, Counselors\, Drug and Alcohol Counselors\, Marriage and Family Therapists\, Case Managers\, Nurse Practitioners
Oppositional Defiant Disorder doesn’t have to be complicated! This web course provides mental health professionals with a three-step approach to treating the signs and symptoms of ODD and co-occurring disorders in children and teens\,
ages 4-14.
Full Description\:
Confronting Defiance
According to the AACAP\, evidence suggests that between 1 and 16% of children and adolescents have Oppositional Defiant Disorder (ODD). Challenged by basic rules of society\, this disorder causes a struggle between the parent and child and
ultimately the therapist and child. Tantrums\, arguing\, defiance\, blaming\, and anger when left untreated may disrupt classrooms\, strain families\, and lead to a risk of juvenile delinquency. Conflict may also go on to affect the
behavioral\, academic\, and social success of the child.
This webinar discusses ODD\, similar disorders\, and the effect on young children and teens. Using a three-step approach to intervention called SimpleThree\, mental health professionals will learn how to treat ODD symptoms in children and
adolescents as well as educate parents to reinforce good behavior to maintain success.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Identify Oppositional Defiant Disorder\, children at risk\, and differentiate from similar childhood diagnoses by etiology and behavior
Apply a three-step\, evidence-based approach to intervention called SimpleThree with defiant children ages 4-14
Incorporate a behavioral modification system using clear\, measurable rules to encourage good behavior and structure
Learn how to strategically follow up with families to reinforce effective parenting skills and maintain success and support with easy-to-access resources
Your Presenter\:
WARD HALVERSON\, LCSW-R\, M.Ed.\, is a licensed clinical social worker and educator with over 12 years of experience as well as a former school teacher\, army veteran and medical officer\, and father. He received a master’s degree in Social
Work from Syracuse University and a master’s degree in education from The College of Saint Rose. Mr. Halverson currently runs an outpatient mental health private practice where he specializes in the treatment of child and family
defiance\, anxiety\, and trauma\, and has developed the SimpleThree system to approach these issues with his clients as well as other mental health professionals.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting
15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\:
https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Social Workers\, Psychiatric Nurses\, School Nurses\, Psychiatric Nurse Practitioners\, Licensed Professional Counselors\, Marriage and Family Therapists\, Psychologists\, Educators\, School Social Workers\, School Administrators\, Foster Care
Professionals\, Parents\, Clergy
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120611T160000Z DTEND;VALUE=DATE-TIME:20120611T173000Z UID:http://www.webinarcentral.net/content/how-establish-effective-good-clinical-practice-drugs-and-medical-devices-webinar-complianceo URL;VALUE=URI:http://www.webinarcentral.net/content/how-establish-effective-good-clinical-practice-drugs-and-medical-devices-webinar-complianceo SUMMARY:How To Establish An Effective Good Clinical Practice in Drugs and Medical Devices - Webinar By ComplianceOnline DESCRIPTION:This 90-minute webinar will help you establish an effective Good Clinical Practice (GCP) by providing a current\, accurate and complete (CAC) review and understanding of the relevant and applicable regulations for clinical trials or studies\, the requirements and compliance in a systematic\, integrative (SI) manner.
Why Should You Attend\:
To be able to achieve sustainability and to remain sustainable and competitive in global medical product markets\, it is necessary to streamline regulatory compliance processes\, in particular\, the Good Clinical Practice (GCP) for clinical trials and studies and beyond. To establish and maintain GCP\, it is critical to accurately define\, document and implement “current\, accurate\, and complete” (CAC) requirements pursuant to the relevant and applicable laws and regulations\, GCP requirements\, and compliance in a systematic\, integrative (SI) manner.
This webinar is intended to help you establish an effective Good Clinical Practice (GCP) by providing a current\, accurate and complete (CAC) review and understanding of the relevant and applicable regulations for clinical trials or studies\, the requirements and compliance in a systematic\, integrative (SI) manner\, all of which are regulated by the United States Food and Drug Administration (FDA). At the end of this webinar\, you will leave empowered with the knowledge of applicable FDA regulations and requirements.
Areas Covered in the Seminar\:
Overview\: Major postmarketing vigilance revisions are now in force. A revised medical device guidance document on postmarketing vigilance (MEDDEV 2.12-1 rev 5) came into force on January 1\, 2008. Providing more guidance than the previous version\, the new document includes new reporting terminology and concepts such as \\"periodic summary reporting\\" and \\"trend reporting.\\"
In addition\, the terms \\"advisory notice\,\\" \\"near incident\,\\" and \\"recall\\" have been eliminated or replaced. Although MEDDEVs are not legally binding\, it is likely that all European Competent Authorities will follow the new guidelines and will expect organizations involved in the management and reporting of adverse incidents to follow them as well. This session will address topics such as new definitions\; the guideline's extended scope\, reporting criteria/timelines\, filing safety notices and field safety corrective actions\, and more. The new guidelines contain some controversial aspects\, including the extension of their scope and the new approach of immediate reporting unless delays can be justified. However\, they also provide additional clarity and more-detailed advice in many areas. The European Database EUDAMED also is described. Periodic or trend reporting under certain conditions is now allowed\, as a result of the integration of certain GHTF concepts. Although a transition period was allowed until the end of 2007\, the revised guidelines will undoubtedly result in the need for manufacturers\, authorized representatives\, and distributors to make changes to their SOPs and other documents.
Areas Covered in the Session\:
Examine the latest changes to MEDDEV and Medical Device Vigilance and impact on medical device manufacturers
Recognize the \\"new\\" terminology and concepts
Report incidents as recommended by the guidance
Examine why Global Harmonization Task Force (GHTF) is an integral component of the new postmarketing vigilance guidelines
Manage expectations for reporting and timelines
Recognize which amendments impact the European vigilance system
Interpret the new guidelines that cover incidents involving devices that carry the CE mark and devices that do not carry the CE mark
Submit periodic summary reports of incidents to Competent Authorities
Examine controversial aspects of the guidelines\, including the extension of their scope and the new approach of immediate reporting unless delays can be justified
Identify the conditions under which reporting is not required and why they have been expanded and clarified with no significant changes\, although one reason has been removed
Who Will Benefit\: This webinar will provide valuable assistance and guidance to device companies in involved in vigilance reporting. Employees who will benefit include\:
All levels of management and departmental representatives and those who desire a better understanding or a \\"refresh\\" overview
Regulatory Affairs
Clinical Affairs
Quality and Compliance
Marketing &\; Sales
Distributors
Engineering/Technical Services/Operations
Consultants
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: This webinar will cover the various methods used to determine residual moisture in products ranging from bulk powders\, to sterile freeze-died products in vials\, to foods. Understanding the different techniques\, their limitations\, and proper execution will result in more accurate and precise moisture results\, which translates into better quality products with longer shelf lives.
Why you should attend\: Monitoring and controlling residual moisture in powders\, lyophilized solids\, foods\, etc can be a critical factor in achieving and maintaining quality products throughout their expected shelf life. Improper levels of moisture in products can result in poor powder flow properties\, spoilage\, polymorph changes\, changes in compaction properties\, microorganism growth promotion\, higher degradation kinetics\, and in the case of freeze-dried products\, loss of physical structure and changes in reconstitution properties. There are several methods typically employed to determine residual moisture\, and the choice of method will be based on the sample tested\, the level of residual moisture present\, and the accuracy and precision required for testing. Additionally\, many of these methods require a skill and knowledge in preparing and testing the samples if accurate results are to be achieved. In fact\, in many cases\, samples containing very low residual moisture\, as in the case with freeze-dried products\, accurate results for residual moisture are not achieved simply due to improper sample preparation and handling. Additionally\, inaccurate and or imprecise results will be obtained if the correct method for testing residual moisture is not chosen. In addition to covering the various techniques employed for residual moisture testing\, this seminar will pay particular attention to choosing the correct technique for a specific application\, specific details of sample preparation\, sample handling\, and data analysis\, all of which can affect the final result. Additionally\, a high throughput\, non-destructive technique will be discussed\, which can be used\, if applied correctly\, for very rapid and accurate testing with 100% sample recovery.
Areas Covered in the Session\:
Thermal properties of formulated products
How and where residual moisture is trapped in products
Effects of residual moisture on dried products
Gravimetric methods for residual moisture testing
Near infrared spectroscopy method for residual moisture testing
Volumetric Karl Fischer titration
CoulometricKark Fischer titration
Specialized methods of residual moisture testing
Proper handling techniques for external extraction in sealed vials
Learning objectives\:
Choosing the correct residual moisture test for your applications
Understanding the advantages and disadvantages of the different techniques covered
Understanding (via a step by step method) the propertechnique for conducting a coulometric Karl Fischer external extraction (including equations)
Who Will Benefit\: This webinar will provide valuable assistance to those companies involved in the handling of powders\, lyophilized products\, solid pharmaceutical dosage forms\, and dried foods.
Quality Control Scientists
Development Scientists
Production Management
Quality Assurance
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
This FDA warning letter closeout program will discuss how to successfully complete warning letter close out program which will help firm to obtain a closeout letter from FDA.
Why Should You Attend\:
FDA Commissioner Margaret Hamburg recently announced several new enforcement initiatives. Part of the \\"new FDA\\" is the increased issuance of warning letters and the creation of a warning letter \\"closeout\\"\, which regulated firms can use to your advantage.
FDA's warning letter program has changed substantially and more warning letters will be issued - and faster! In the past\, firms that received a warning letter from FDA were subject to unending scrutiny\, speculation and financial challenge. But now warning letter recipients will have the chance to prove they are back in compliance. \, FDA will provide a manner for a firm to demonstrate that it has complied with the terms of an enforcement action. The warning letter closeout program has begun as of September 2009. All firms who receive a warning letter will have the opportunity to obtain a \\"closeout\\" letter from FDA. Firms that fail to obtain a closeout letter will be clearly identified as still being under FDA scrutiny.
Attend this Webinar to know everything about warning letters\, warning signs\, issuance\, company’s response and how to rectify the FDA warning letter close out mistakes.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120612T200000Z DTEND;VALUE=DATE-TIME:20120612T200000Z UID:http://www.webinarcentral.net/content/integrating-art-therapy-your-professional-practice-4 URL;VALUE=URI:http://www.webinarcentral.net/content/integrating-art-therapy-your-professional-practice-4 SUMMARY:Integrating Art Therapy into Your Professional Practice DESCRIPTION:This one-hour webinar provides attendees with a definition of art therapy\, its benefits\, &\; how it differs from verbal therapy. Case studies will
be presented to assist attendees in identifying indicators &\; key images in their clients’ art.
Full Description\:
This webinar program provides definitions of what Art Therapy is and how it differs from verbal therapy. The role of art-making in diagnosis and
treatment is addressed through assessment by examining age-appropriate drawing skills and the symbolism of images that have personal meaning to
our clients. In addition\, this course examines art-making as personal growth and its therapeutic benefits. The attendees will learn specific
indicators to look for in their clients’ art work and how to identify key images through the presentation of several case studies. Through these
case studies the participants will identify how clients can express their mood through drawing and painting. Psychological and behavioral
problems\, such as regression and impairments\, will be identified through the symbolism in clients’ art work.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
1.Discover a new method of communicating with clients
2.Examine effective Art Therapy techniques
3.Understand the therapeutic power that art provides
4.Acquire skills for assessing the client’s stress level
5.Discuss current research as it relates to Art Therapy and its effectiveness with clients
Your Presenter\:
Pamela M. Hayes\, MFT\, LMHC\, ATR-BC\, is an artist and a registered and board certified Art Therapist. She is licensed as a Marriage and Family
Therapist and Mental Health Counselor and is currently in private practice in Los Angeles\, California. Ms. Hayes developed the art therapy
program at the Rhode Island School of Design. For the past 15 years\, Ms. Hayes has worked in numerous psychiatric settings. Currently\, her focus
includes families\, couples\, adults\, and children struggling with mood and anxiety disorders\, addiction\, eating disorders\, abuse\, and grief-
related issues. Ms. Hayes has an undergraduate degree in Fine Arts from Parsons School of Design in New York City and a graduate degree in
Marriage and Family Therapy and Art Therapy from Notre Dame de Namur University in Belmont\, California. For more information about Ms. Hayes\,
please visit her website at\: www.hayesarttherapy.com
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to
attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound
quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save
time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Marriage and Family Therapists\, Licensed Professional Counselors\, Social Workers\, Psychiatric Nurses\, Drug and Alcohol Abuse Counselors\,
Pediatricians\, Physicians\, Art Therapists\, Pastoral Counselors\, Guidance Counselors\, Youth Pastors\, Youth Counselors\, Educators
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120613T064600Z DTEND;VALUE=DATE-TIME:20120613T064600Z UID:http://www.webinarcentral.net/content/management-controls-under-qsr-and-iso-13485-webinar-globalcompliancepanel URL;VALUE=URI:http://www.webinarcentral.net/content/management-controls-under-qsr-and-iso-13485-webinar-globalcompliancepanel SUMMARY:Management Controls Under QSR and ISO 13485 - Webinar By GlobalCompliancePanel DESCRIPTION:regulatory requirements are met. This concept is codified in both the QSR and ISO 13485. FDA officials have repeatedly stated that the management controls subsystem is the central subsystem because it is the \\"glue that holds the quality system together.\\"
Since it is individuals in top management that the FDA will typically seek to fine or prosecute in the event of major noncompliance\, this session is key for those individuals who are members of top management\, or those regulatory professionals who need to understand these requirements to assure top management is fulfilling its responsibilities. This session will discuss the requirements for Management Controls\, including organizational structure\, internal audits\, establishment of a quality policy and confirmation it is being followed\, establishment and contents of a quality system and quality plan\, and of course all aspects of management reviews.
Areas Covered In the Seminar\:
QSR and ISO 13485 requirements for management controls
Organizational structure
Establishment of an internal audit program
Establishment of your company's quality policy
Contents of your company's quality plan
How/when to conduct management reviews
Who will benefit\:
Regulatory Management
Quality Assurance Professionals
Consultants
Sales/Marketing Management
Senior and mid-level Management
Quality System Auditors
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: The U.S. Food and Drug Administration issued the final rule establishing regulations to require current good manufacturing practices (CGMPs) for dietary supplements.
The current good manufacturing practices (CGMPs) final rule will require that proper controls are in place for dietary supplements so that they are processed in a consistent manner\, and meet quality standards. The CGMPs apply to all domestic and foreign companies that manufacture\, package\, label or hold dietary supplements\, including those involved with the activities of testing\, quality control\, packaging and labeling\, and distributing them in the U.S. The rule establishes CGMPs for industry-wide use that are necessary to require that dietary supplements are manufactured consistently as to identity\, purity\, strength\, and composition. The requirements include provisions related to\: the design and construction of physical plants that facilitate maintenance\, cleaning\, proper manufacturing operations\, quality control procedures\, testing final product or incoming and inprocess materials\, handling consumer complaints\, and maintaining records.
Dietary Supplement manufacturing sites have been increasingly inspected by the FDA for compliance with the GMPs\, and warning letters have been issued. In the face of the increasing scrutiny by the FDA\, it is incumbent on dietary supplement manufacturers to understand the regulations and to implement documentation and procedures that will ensure compliance.
Why should you attend\: The regulations require that you understand the requirements and establish a Quality System designed to meet them. This presentation will review the requirements and the rationale for them.
Areas Covered in the Session\:
History of the regulations and their current status
Review of the key points of the regulations
Discussion of methods that can be used to comply with the regulations
Documentation that is required for compliance
The role of the Quality organization
What to expect during an FDA inspection
How to respond to an FDA inspection
Raw material control and incoming inspection
Cleaning and Maintenance
\\Who Will Benefit\:
Senior Management
Quality Control Management and personnel
Manufacturing management and supervisors
Warehouse Management and supervisors
Shipping and Distribution Management and supervisors
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
This one-hour webinar will introduce attendees to the interpersonal dynamics of childhood peer aggression and interventions for victims and aggressors. Current research on treatment and prevention will also be discussed.
Full Description\:
The Interpersonal Dynamics of Bullying
This webinar will provide an understanding of the interpersonal dynamics of childhood peer aggression\, also referred to as bullying. Understanding the fundamental elements of this unique relationship will help attendees distinguish bullying from usual peer conflicts. The short and long-term effects of victimization will be reviewed including the “bully victim” who often normalizes antisocial behavior. We will discuss interventions for victims and aggressors and cover recent research suggesting that structural family therapy and solution-focused family therapy are effective at reducing the abusive behavior of aggressors as well as assisting victims. In cases where family therapy is not an option\, viable alternatives (individual and group cognitive therapy) are also reviewed. Additionally\, recent research on prevention will be included.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Discuss the unique interpersonal dynamics of childhood peer aggression and victimization
Define the personality and behavioral traits of children who are aggressive toward peers
Assess the impact of childhood peer aggression on the victim
Discuss basic theory and practice of structural family therapy\, solution-focused family therapy\, and cognitive therapy for aggressors and victims
Examine the results of the research on effective prevention of childhood peer aggression
Your Presenter\:
THOM MOTE\, M.Ed.\, LPC\, is a privately practicing counselor in Northwest Georgia and Chattanooga\, Tennessee. His 16 years of counseling experience include specializing in adjustment therapy\, life transitions\, and grief counseling with individuals\, couples\, and families. He has presented numerous workshops to live and television audiences on topics such as abusive youth\, structured parenting\, positive psychology\, and compassion fatigue.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Social Workers\, Psychologists\, Counselors\, Play Therapists\, Juvenile Justice Personnel\, Nurses\, Psychiatric Nurses\, Nurse Practitioners\, Educators\, Marriage and Family Therapists\, Alcohol and Drug Abuse Counselors\,Parents
Is your clinical systems production environment bloated with studies that should be archived? Do you long for an easy way to create and refresh a training environment? Are you struggling with the complexities of migrating studies to a new environment? Does your clinical team desire the power of diagnosing production issues in a test environment without having to involve a database administrator? Look no further. Accel-Copy can do all this and more!
BioPharm Systems has developed Accel-Copy to be a versatile tool that allows your clinical environment to be managed by your clinical team more effectively.
Out of the box\, the application provides the following features and benefits\:
Database Management\:
Migrate select global library domains/studies
Archive studies/global library to an archived instance
Support and Training Functionality\:
Refresh studies or parts of studies from production to development or QA
Refresh patient data/discrepancies from production to development or QA
Create/refresh training instance studies or parts of studies
Clinical Administration and Configuration\:
Synchronize reference code lists among environments
Refresh sites and investigators among environments without replication
Manage organization units\, regions\, program\, and projects across environments from a single source
Data Quality\:
Perform field by field comparison of database data from before and after a migration/upgrade
Copy global library domains from production to QA
Copy a new study to production from QA
The application is fully documented\, validated\, and GxP compliant.
Please join Michelle Engler\, the creator of Accel-Copy\, for this one-hour presentation that will include a live demonstration of this powerful solution.
For more information about BioPharm Systems\, visit\: http\://www.biopharm.com
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120614T150000Z DTEND;VALUE=DATE-TIME:20120615T220000Z UID:http://www.webinarcentral.net/content/medical-device-sterilization-corrective-preventive-action-seminar-complianceonline URL;VALUE=URI:http://www.webinarcentral.net/content/medical-device-sterilization-corrective-preventive-action-seminar-complianceonline SUMMARY:Medical Device Sterilization\: Corrective & Preventive Action - Seminar By ComplianceOnline DESCRIPTION:Course Description \:-
Sterilization is a critical aspect of device approval and release. Though this is indeed fact\, manufacturers sterilize product as a matter of course\, without expert sterilization assurance personnel to guide them through potential problems in sterilization. As the world and meaning of CAPA continue to evolve in the medical device industry\, further misunderstanding arises when faced with determine root cause and corrective (or preventive) action for any variation in this critical process in device manufacture.
The course will begin with an overview of EO sterilization\, explaining which aspects of the process often cause confusion. This will be followed by process validation and what paperwork is required to provide ‘documented evidence’ \; and finally what are typical deficiencies encountered in the EO process. Next a detailed explanation of Radiation Sterilization will be given. Specific to Radiation Sterilization is the required sterilization dose\, which will be covered in depth – how to determine sterilization dose and how to maintain the validated dose. Process validation will be covered as well as the typical deficiencies encountered in Radiation Sterilization and Validation. Critical and non-critical deficiencies will be covered and when this should trigger a CAPA. Finally contract sterilization will be reviewed with the specifics of how to deal with CAPA when you are not directly responsible for sterilization.
Who will Benefit\:-
This course will be beneficial to the following personnel in Medical Device Manufacturing and Sterilization facilities\:
This webinar will present a methodology for system assessment\, risk-analysis\, 21CFR Part 11 compliance\, remediation and inventory\, along with templates and forms that attendees can modify for their own business.
Why Should You Attend\:
Can you show me how you manage your computer systems in compliance with 21CFR Part 11?
This presentation will describe a process which has prepared several companies to answer this question from FDA inspectors accurately\, completely and to the great satisfaction of the inspectors. We will show how to inventory the site\, assess the compliance risk of existing systems\, implement new systems\, remediate any non-compliance found\, prepare SOPs and quality policies\, collate the required documentation and train the staff.
Attendees will learn how to prepare and present a concise and comprehensive presentation to regulatory inspectors. Preparation and knowing in advance the expectations and required deliverables for a successful inspection is critical to your pharmaceutical\, medical device\, biotechnology or software company. Case studies will be presented showing the outcomes for three inspections at companies following this methodology.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120614T160000Z DTEND;VALUE=DATE-TIME:20120614T170000Z UID:http://www.webinarcentral.net/content/rems-update-risk-evaluation-and-mitigation-strategies-webinar-complianceonline URL;VALUE=URI:http://www.webinarcentral.net/content/rems-update-risk-evaluation-and-mitigation-strategies-webinar-complianceonline SUMMARY:REMS Update\: Risk Evaluation and Mitigation Strategies - Webinar By ComplianceOnline DESCRIPTION:This webinar on Risk Evaluation and Mitigation Strategy (REMS) will help you understand how to adhere to REMS policy\, its implementation and submission requirements. It will discuss FDA's current thinking on REMS\, how it reduces the REMS obligations for sponsors\, and how the agency's requirements and procedures in this area are evolving.
Why Should You Attend\:
Risk Evaluation and Mitigation Strategy (REMS) continues to be a critical part of the FDA’s focussed efforts to increase safety of marketed products (drug or biological). As such they are enforceable by civil monetary penalties of up to $250\,000 per violation that can continue to double for subsequent 30-day periods\, up to $1 million per period\, $10 million per proceeding. Products in violation of REMS requirements may not (continue to) be introduced into interstate commerce.
Proper adherence to REMS regulations is critical. However\, the implementation of a REMS can be challenging. It must be undertaken by a specified protocol\, departure from which requires agreement with the FDA. This webinar will explain the above. Participants will understand when a REMS will be required\, the elements that need to be included in the REMs needed for their product\, as well as details of the two-part format required for submission\: the proposed REMS and the more detailed REMS supporting documents. Also\, the FDA requirements and procedures continue to evolve. We will adress the agency's current thinking in some instances and show how they reduce the REMS obligations for sponsors.
Learning Objectives\:
This webinar is designed to educate participants about art therapy and provide practical skills for effective assessment and intervention with
clients experiencing symptoms of anxiety.
Full Description\:
This webinar is designed to educate participants about art therapy and provide practical skills for effective assessment and intervention with
clients experiencing symptoms of anxiety. Demonstrations of art therapy techniques will advance the participants’ understanding of the bio
psychosocial perspective of many of the disorders that fall under the category of “anxiety\,” including phobias\, PTSD\, panic\, as well as sleeping
and eating disorders. Significant attention will be paid to treatment interventions with numerous opportunities for hands-on art-based
techniques.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
1.Discover an alternative method of communicating with clients suffering with anxiety—including PTSD\, Phobias\, Acute Stress\, Eating Disorders\,
Sleep Disorders\, and Panic Attacks
2.Identify effective Art Therapy techniques and learn how to implement them in session
3.Examine the therapeutic power that art provides in reducing stress and understanding fears
4.Acquire skills for assessing and treating anxiety
5.Discuss various art tasks and experience the healing process to promote coping skills in life
Your Presenter\:
Pamela M. Hayes\, MFT\, LMHC\, ATR-BC\, is an artist and a registered and board certified Art Therapist. She is licensed as a Marriage and Family
Therapist and Mental Health Counselor and is currently in private practice in Los Angeles\, California. Ms. Hayes developed the art therapy
program at the Rhode Island School of Design. For the past 15 years\, Ms. Hayes has worked in numerous psychiatric settings. Currently\, her focus
includes families\, couples\, adults\, and children struggling with mood and anxiety disorders\, addiction\, eating disorders\, abuse\, and grief-
related issues. Ms. Hayes has an undergraduate degree in Fine Arts from Parsons School of Design in New York City and a graduate degree in
Marriage and Family Therapy and Art Therapy from Notre Dame de Namur University in Belmont\, California. For more information about Ms. Hayes\,
please visit her website at\: www.hayesarttherapy.com.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to
attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound
quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save
time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Marriage and Family Therapists\, Licensed Professional Counselors\, Social Workers\, Psychiatric Nurses\, Drug and Alcohol Abuse Counselors\,
Pediatricians\, Physicians\, Art Therapists\, Pastoral Counselors\, Guidance Counselors\, Youth Pastors\, Youth Counselors\, Educators
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120618T150000Z DTEND;VALUE=DATE-TIME:20120618T150000Z UID:http://www.webinarcentral.net/content/complianceonline-and-risk-luminosity-seminars-rls-presents-risk-management-summit URL;VALUE=URI:http://www.webinarcentral.net/content/complianceonline-and-risk-luminosity-seminars-rls-presents-risk-management-summit SUMMARY:ComplianceOnline and Risk Luminosity Seminars (RLS) presents the Risk Management Summit DESCRIPTION:Course Description\:
In this program we will explore the role of leadership\, technology\, and the decision sciences play in creating the right environment for business performance and risk management to co-exist. One of the common denominators of recent business failure from Enron to MF Global has been the inability of business leaders to manage increasingly complex risks in the pursuit of business performance. This program will provide innovative approaches to address decision-making under uncertain conditions. The Risk Luminosity Seminar will provide the participant with new tools to address risk management whether you are in healthcare\, energy exploration\, finance\, industry or a federal agency struggling with how to add value to your risk management program.
Who will Benefit
CEOs\, CFOs\, CIOs\, COOs\, VPs\, Directors\, Board Trustees\, Regulatory affairs\, Senior officers in Risk Management and Compliance
This webinar on issue detection and escalation in clinical trial settings will review the responsibilities of sponsors\, investigators\, IRB\, vendors and CROs in clinical trial setting to maintain compliance. We will discuss how you can proactively monitor to prevent issues and in case of issue detection\, escalate them.
Why Should You Attend\:
In recent years the FDA has increased the number of clinical sites and trials that have been inspected and audited. The number of investigators under investigation or disqualified has increased. IRBs have been inspected and issued with 483 letters.
What would happen\: If the site enrolls some subjects that don't meet all the entry criteria? Have unreported safety issues? Don't sign the CRF? Are not accurate in reporting the data? Don't follow their own SOP? Are these issues hidden in your monitoring reports or not there at all? The FDA does conduct audits of the sites and will issue 483 letters to either the sites or to sponsors. During a market review of data submitted for example an NDA they can disqualify the data if not consistent\, they can disqualify a site if they have had protocol\, GCP or SOP deviations. They can disqualify a whole study or application if the issues are systemic. Do you have the processes to assure compliance?
Areas Covered in the Seminar\:
Understand 10 step Risk based approach to validation\, explore methods to decrease resource requirements and make documentation more manageable and understandable.
Why Should You Attend\:
This session explores proven techniques that reduce validation project time\, often to one-third. Learn efficient documentation strategies for computer system validation and how to increase overall system productivity. The 10-step risk-based validation approach is detailed so that the specific documents for a validation project are understood. Explore methods to decrease resource requirements\, and make documentation more manageable and understandable. This often results in a savings of two-thirds the cost. Additionally\, this course will help companies increase compliance and demonstrate how to use risk management to improve system performance and promote process improvement.
Areas Covered in the Seminar\:
- Learn which documents the FDA expects to audit.
- Proven techniques that reduce software costs and implementation times.
- Increase corporate productivity and individual workforce member productivity.
- Efficiently create validation documentation.
- Decrease resource requirements.
- Make documentation more manageable and understandable.
- Avoid 483s and Warning Letters.
- How to implement a computer system to gain maximum productivity.
- Use resources effectively to perform effective validation while avoiding doing too much.
- How to link requirements\, specifications\, risk management\, and testing.
Discover multiple classes of antidepressants and how they are used inside and outside of treating depression.
Full Description\:
This one hour webinar will introduce participants to the various classes of antidepressant drugs\, arranged according to the dates of their introduction into medicine. General uses\, side effects\, effects in pregnancy\, and uses outside of treating depression will be emphasized within each category. Having knowledge of the side effects will allow the non- prescriber to monitor for adverse effects that may limit a patient's daily functioning. We will also discuss withdrawal and overdose syndromes where applicable. Finally\, we will explore the STAR-D study results to attain a detailed description of the efficacy of these drugs to relieve depression.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Discuss the uses of antidepressants as antidepressants\, anxiolytics\, and analgesics
Identify the mechanisms through which these drugs relieve depression\, including references for further self-study
Examine the limitations of tricyclic antidepressants and the side effects to watch for in clinical practice
Discover what SSRI means\, the different serotonin receptors\, and common side effects of use as well as withdrawal distress (including serotonin withdrawal syndrome in the neonate)
Understand why dopaminergic agonist antidepressants can cause\, rather than relieve\, anxiety
Your Presenter\:
Robert M. Julien\, MD\, PhD\, is both an anesthesiologist and psychopharmacologist with over 40 years of experience. He received his PhD from the University of Washington in 1970 and his MD from the University of California at Irvine in 1977. Previously an Associate Professor of Pharmacology and Anesthesiology at the Oregon Health Sciences University\, Dr. Julien lectures widely on psychopharmacology. With over 36 years of continuous publication\, Dr. Julien's psychopharmacology textbook\, A Primer of Drug Action (Worth Publishers)\, is regarded as the definitive textbook of psychopharmacology\, covering both psychotherapeutic agents as well as substances of abuse. Dr. Julien is a nationally recognized speaker and expert in psychopharmacology.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Pharmacists\, Psychologists\, Social Workers\, Counselors\, Drug and Alcohol Counselors\, Marriage and Family Therapists\, Case Managers\, Nurse Practitioners
Oppositional Defiant Disorder doesn’t have to be complicated! This web course provides mental health professionals with a three-step approach to treating the signs and symptoms of ODD and co-occurring disorders in children and teens\,
ages 4-14.
Full Description\:
Confronting Defiance
According to the AACAP\, evidence suggests that between 1 and 16% of children and adolescents have Oppositional Defiant Disorder (ODD). Challenged by basic rules of society\, this disorder causes a struggle between the parent and child and
ultimately the therapist and child. Tantrums\, arguing\, defiance\, blaming\, and anger when left untreated may disrupt classrooms\, strain families\, and lead to a risk of juvenile delinquency. Conflict may also go on to affect the
behavioral\, academic\, and social success of the child.
This webinar discusses ODD\, similar disorders\, and the effect on young children and teens. Using a three-step approach to intervention called SimpleThree\, mental health professionals will learn how to treat ODD symptoms in children and
adolescents as well as educate parents to reinforce good behavior to maintain success.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Identify Oppositional Defiant Disorder\, children at risk\, and differentiate from similar childhood diagnoses by etiology and behavior
Apply a three-step\, evidence-based approach to intervention called SimpleThree with defiant children ages 4-14
Incorporate a behavioral modification system using clear\, measurable rules to encourage good behavior and structure
Learn how to strategically follow up with families to reinforce effective parenting skills and maintain success and support with easy-to-access resources
Your Presenter\:
WARD HALVERSON\, LCSW-R\, M.Ed.\, is a licensed clinical social worker and educator with over 12 years of experience as well as a former school teacher\, army veteran and medical officer\, and father. He received a master’s degree in Social
Work from Syracuse University and a master’s degree in education from The College of Saint Rose. Mr. Halverson currently runs an outpatient mental health private practice where he specializes in the treatment of child and family
defiance\, anxiety\, and trauma\, and has developed the SimpleThree system to approach these issues with his clients as well as other mental health professionals.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting
15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\:
https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Social Workers\, Psychiatric Nurses\, School Nurses\, Psychiatric Nurse Practitioners\, Licensed Professional Counselors\, Marriage and Family Therapists\, Psychologists\, Educators\, School Social Workers\, School Administrators\, Foster Care
Professionals\, Parents\, Clergy
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120620T180000Z DTEND;VALUE=DATE-TIME:20120620T180000Z UID:http://www.webinarcentral.net/content/medical-device-supplier-quality-agreements-webinar-globalcompliancepanel URL;VALUE=URI:http://www.webinarcentral.net/content/medical-device-supplier-quality-agreements-webinar-globalcompliancepanel SUMMARY:Medical Device Supplier Quality Agreements - Webinar By GlobalCompliancePanel DESCRIPTION:Overview\: The FDA’s Quality System Regulation (QSR) explains how a device manufacturer must manage suppliers. This ranges from supplier evaluation and selection to control methods. One common approach uses a supplier quality agreement. This webinar explains the elements of a supplier quality agreement and its implementation.
Why should you attend\: Effective supplier management can help prevent problems and reduce their impact should they occur. With the increased emphasis on supplier management\, you can expect strong coverage of this area during an FDA Inspection.
You need to understand the QSR requirements\, good business practices\, and the role of a quality agreement. This webinar will help you set up an effective system.
Areas Covered in the Session\:
Valuable documents that provide understanding
Quality System Regulation (QSR)\, including the definitions
QSR Preamble
ISO 13485\:2003
FDA's Quality System Inspection Technique (QSIT) manual
Warning Letters
Subject Areas covered
QSR Requirements for Purchasing
The Supplier Quality Agreement
Administrative Elements
Compliance
Manufacturing\, Packaging\, and Labeling
Documentation and Records
Storage and Shipment
Change Control
Non-Conformance\, CAPA\, and Complaints
Auditing
For each subject area\, the webinar includes information from the valuable documents listed above
Who will benefit\:
Quality Managers
Regulatory Affairs Managers
Risk Managers
Supply Chain Managers
Purchasing Professionals
Supplier Management Team
Customer Complaint Specialists
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Overview\: This webinar will examine the stated intent of the Agency to get tougher across the board in its expectations for the medical industry and its compliance to the cGMPs.
It will examine how these goals of the Agency have translated into action over the past two plus years\: The changing focus of QSIT re\: medical devices\, and ICH Q8\, Q9\, and Q10 re\: pharmaceuticals\; Multi-site company operations\, and the supply chain\; Trends evident in 483 observations\, Warning Letters\, and recent major industry failures\; Emphasis on proving a company is \\"in control\\" to an investigator's satisfaction\; the negative role of \\"entropy\\"\, and proactive and reactive Warning Letter avoidance techniques.
Why you should attend\: The last few years have seen several major \\"names\\" in drugs and devices stumble over cGMP issues\, resulting in recalls\, lawsuits\, and even possible criminal prosecution. As a result\, there has been a major shift in the emphasis of the U.S. FDA cGMP compliance audit\, also affecting clinical trial expectations\, product submissions and company response requirements. This change in focus has a major impact on interpretation of individual compliance objectives\, cGMP objectives\, and measurements of success. Recent negative publicity on pharmaceuticals\, devices\, as well as events in unrelated industries has put pressure on the Agency to \\"get tough on compliance / enforcement\\". The public wants change. The U.S. FDA is responding. The cGMP compliance audit\, validations\, 510(k) submissions / data\, \\"better science\\"\, lifecycles\, closed-loop CAPA\, outsourcing / globalization and supply chain / control issues\, and senior management\, are all under more intense scrutiny.
Areas Covered In the Session\:
The Changed / Tougher FDA.
Shifting and New Emphasis
Core Expectations
QSIT and Q10 Focus\; and Q8 and Q9 \\"Lessons\\"
High Risk Areas
The Supply Chain
The Multi-Site Challenge
What Constitutes \\"Proof\\"
Addressing the On-site Audit\, the 483s\, the Remediation / Responses
Who will benefit\:
Senior Management in Drugs\, Devices\, Biologics\, Dietary Supplements
QA
RA
R&\;D
Engineering
Production
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Discover why Inattentive ADHD is different from other types of ADHD and learn the latest information about screening\, SCT\, symptomatology\, comorbidities\, treatment modalities\, medication\, and how this disorder may be mentioned in DSM-5.
Full Description\:
Why is Inattentive ADHD Different? New Information
Attention-Deficit Hyperactivity Disorder\, Predominately Inattentive Type is NOT a “calmer” or “lighter” version of ADHD. The neurophysiology\, symptoms\, treatment methods\, and medications for this disorder are different than the other types of ADHD. Since patients with Inattentive ADHD are not typically as disruptive as those with other types of ADHD\, this type is commonly misunderstood or goes unrealized by the mental health professional. Little research has been done compared to Combined ADHD and most seminars and webinars only spend a small portion of time on Inattentive ADHD.
This one-hour course will provide participants with the latest information about screening\, Sluggish Cognitive Tempo (SCT)\, symptomatology\, comorbidities\, treatment modalities\, medication\, and how Inattentive ADHD may be mentioned in DSM-5.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Identify the differences between Attention-Deficit/Hyperactivity Disorder\, Predominately Inattentive Type (Inattentive ADHD)\, and other forms of ADHD
Define treatment methods for Inattentive ADHD and how such methods are different than those for other forms of ADHD
Outline the common co-morbidities of Inattentive ADHD
Evaluate new research about Sluggish Cognitive Tempo and its relationship to ADHD
Discuss how Inattentive ADHD may be described in DSM-5
Your Presenter\:
KEVIN T. BLAKE\, PhD\, P.L.C.\, is a licensed psychologist and author with over 20 years of experience as a nationally recognized authority on learning disorders and ADHD in children\, adolescents\, and adults. This interest spurred from his own struggles overcoming a reading disorder/dyslexia and hearing impairment.
Dr. Blake serves as a member of the American Psychological Association\, International Dyslexia Association\, Children and Adults with Attention Deficit Disorders\, Learning Disabilities Association\, and the National Attention Deficit Disorder Association and was a 1991 delegate to the National Institute for Literacy’s “LEAD 2000 Congress\,” where he advised Congress on diagnostic and remediation issues.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Psychologists\, Social Workers\, Licensed Professional Counselors\, Marriage and Family Therapists\, School Psychologists\, Guidance Counselors\, Psychiatric Nurses\, Nurses\, Psychiatric Nurse Practitioners\, Case Managers\, Alcoholism and Drug Abuse Counselors/Addiction Professionals\, Clergy\, School Administrators\, Physicians\, Psychiatrists\, Mental Health Administrators\, Special Education Teachers\, College Counselors
This webinar will provide a detailed information on the critical requirements of ISO 17025 and recommendations for cost effective implementation. You will learn steps towards laboratory accreditation and how to prepare for an ISO 17025 audit.
Why Should You Attend\:
ISO 17025 is used by laboratories as a standard to develop and establish a Quality System and for the assessment by their clients or by third parties. The standard is also being used as a criterion for laboratory accreditation. ISO 17025 is applicable to all organizations performing tests and/or calibrations\, regardless of the number of personnel or the extent of the scope of testing and/or calibration.
This webinar gives a detailed information on the critical requirements of ISO 17025 and recommendations for cost effective implementation.
Hand-Outs\:
For easy implementation\, attendees will receive
Note\: These complimentary hand-outs will be sent to customers on request. Please email customercare@complianceonline.com for these documents\, stating your order number\, and they will be emailed to you within 4 working days.
Areas Covered in the Seminar\:
Course Description \:-
Nearly every computerized system used in laboratory\, clinical\, manufacturing settings and in the quality process has to be validated. Finding efficiencies without weakening the quality position is essential.
This interactive two-day course explores proven techniques for reducing costs associated with implementing\, using\, and maintaining computer systems in regulated environments.Attendees learn how to decrease software implementation times and lower costs using a 10-step risk-based approach to computer system validation.
The instructor addresses the latest computer system industry standards for data security\, data transfer\,and audit trails. Students see how 21 CFR Part 11\, the FDA regulation pertaining to use of electronic records and signatures\, and the HIPAA electronic security regulations for patient medical records fit into the validation process. Finally\, the instructor reviews recent FDA inspection trends and discusses how to streamline SOP authoring\, revision\, review\, and approval.
This course benefits anyone that uses computer systems to perform their job functions and is ideal for regulatory\, clinical\, and IT professionals working in the health care\, clinical trial\, biopharmaceutical\, and medical device sectors.
Course Objectives \:-
There is a clear trend in the life sciences industry toward outsourcing clinical trial management to clinical research organizations (CROs). If your organization is considering outsourcing\, or already does so\, there are different methods that pharma and medical device companies can use to collect clinical trial management system (CTMS) data from their CRO partners.
Join BioPharm Systems' Param Singh\, vice president of clinical trial management solutions\, for this free one-hour webinar in which he will discuss the overall outsourcing trend\, as well as the pros and cons of the various approaches to sharing CTMS data between sponsors and CROs.
Thursday\, June 21\, 2012 @\:
7\:00 a.m. Pacific Time
8\:00 a.m. Mountain Time
9\:00 a.m. Central Time
10\:00 a.m. Eastern Time
15\:00 UK Time
16\:00 Central European Time
For more information about BioPharm Systems\, please visit www.biopharm.com.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120621T150000Z DTEND;VALUE=DATE-TIME:20120621T150000Z UID:http://www.webinarcentral.net/content/sharing-ctms-data-between-sponsors-and-cros URL;VALUE=URI:http://www.webinarcentral.net/content/sharing-ctms-data-between-sponsors-and-cros SUMMARY:Sharing CTMS Data Between Sponsors and CROs DESCRIPTION:There is a clear trend in the health sciences industry toward outsourcing clinical trial management to clinical research organizations (CROs). If your organization is considering outsourcing\, or already does so\, there are different methods that pharma and medical device companies can use to collect clinical trial management system (CTMS) data from their CRO partners.
Join BioPharm Systems' Param Singh\, vice president of clinical trial management solutions\, for this free one-hour webinar in which he will discuss the overall outsourcing trend\, as well as the pros and cons of the various approaches to sharing CTMS data between sponsors and CROs.
Thursday\, June 21\, 2012 @\:
7\:00 a.m. Pacific Time
8\:00 a.m. Mountain Time
9\:00 a.m. Central Time
10\:00 a.m. Eastern Time
15\:00 UK Time
16\:00 Central European Time
Overview\: Federal laws and regulations mandate to put controls and measures on a company network to ensure security and data integrity. Examples are 21 CFR Part 11\, Sarbanes-Oxley Act\, and HIPAA. With this legislation IT infrastructure and network qualification and compliance become a much more recognizable issue at higher levels of management.
However currently there is no official guideline and the situation is similar to what happened with computer validation in early 90's and with early Part 11 issues. Until there will be an industry wide accepted approach companies either waste valuable resources because doing too much or take a risk to fail inspections because not doing enough or doing it wrong. With FDA's renewed focus on computer validation and IT systems\, industry is looking for advice on how to comply for networks and infrastructure.
This webinar will give a good understanding of FDA requirement and provide recommendations and tools for effective implementation.
Reference material for easy implementation\:
Example\: Network Infrastructure Qualification Plan
SOP\: Risk Based Qualification of Network Infrastructure
SOP\: Qualification of PC Clients
SOP\: Qualification of Data Centers
SOP\: Qualification of Servers
SOP\: Handling Security Patches
Areas Covered in the Session\:
Laws\, regulations and guidelines- 21 CFR Part 11\, HIPAA\, Sarbanes-Oxley
FDA inspection/enforcement practices\: examples for Warning Letters/483s
The FDA Industry Guide\: Cybersecurity for Networks
The GAMP/ISPE Good Practices Guides and the IVT NIQ Standard
Principles and advantages of network infrastructure qualification
Compliance concepts for infrastructure vs. networked systems
Approaches and examples for risk assessment
Configuration management and change control\: the most important steps
Qualification of PC clients\, servers\, data centers
What and how much to test with the risk based cost/benefits in mind
Handling security patches
Dealing with existing/legacy infrastructure
Considerations for network retirement
Dealing with infrastructure for 'CLOUD COMPUTING'
How to maintain the validate state during on-going use
Documentation requirements
Going through a life inspection
Who Will Benefit\:
Analysts
Lab Supervisors and Managers
QA managers and personnel
Analysts
Consultants
Teachers
This 90-minute webinar on sampling plans using ANSI/ASQ Z1.9 will explain the methods in Z1.9 and shows how to use it in a more modern setting (using simple statistical calculators).
Why Should You Attend\:
Many companies use attribute sampling plans at incoming\, in-process\, and final inspection. The common approach uses ANSI/ASQ Z1.4. There is an alternate\, however\, that may reduce cost. Sampling plans based on ANSI/ASQ Z1.9 can reduce cost by requiring smaller sample sizes.
Z1.9 is an effective and efficient method for acceptance sampling. Because it retains the methods required before calculators and spreadsheets\, the standard appears overly complex.
This webinar explains the methods in Z1.9 and shows how to use it in a more modern setting. Participants will learn modern methods based on a simple calculator. The webinar uses the TI-30XA calculator\, but any simple statistical calculator has the required functions.
END:VEVENT BEGIN:VEVENT DTSTAMP;VALUE=DATE-TIME:20120524T190830Z DTSTART;VALUE=DATE-TIME:20120622T180000Z DTEND;VALUE=DATE-TIME:20120622T180000Z UID:http://www.webinarcentral.net/content/risk-assessment-compliance-using-easy-fill-out-documentation-webinar-globalcompliancepanel-0 URL;VALUE=URI:http://www.webinarcentral.net/content/risk-assessment-compliance-using-easy-fill-out-documentation-webinar-globalcompliancepanel-0 SUMMARY:Risk Assessment - Compliance Using Easy To Fill Out Documentation - Webinar By GlobalCompliancePanel DESCRIPTION:Overview\: This webinar teaches how to determine and document risk in a process in order to reduce validation time and ensure compliance.
What makes this session unique are the real life examples that make application of the techniques understandable in the context of any validation project. It includes a workshop for participants to perform their own hazard analysis so they are proficient in applying the risk-based techniques.
Areas Covered in the Session\:
Interactive real life examples.
How to identify risk and establish mitigations.
How to use the hazard analysis to make validation efficient.
How to document the risk assessment using a template
How risk assessment reduces validation time.
Determine risk in a process to reduce the testing effort.
Traceability made automatic
Workshop exercises.
Who Will Benefit\:
IT
QA
QC
Laboratory staff
Managers
GMP\, GCP\, GLP professionals
Price List\:
Live \: $245.00
Corporate live \: $995.00
Recorded \: $295.00
webinars@globalcompliancepanel.com
http\://www.globalcompliancepanel.com
Phone\: 800-447-9407
Fax\: 302-288-6884
Untreated depression in children and adolescents can lead to more serious episodes of depression during adulthood. Drug choice and length of treatment can make a significant difference is the lives of your youngest patients.
Full Description\:
This one-hour webinar will introduce participants to the role of antidepressant drugs in treating depression in children and adolescents. During our time together\, we will examine drug efficacy both with and without adjunctive therapies\, including fluoxetine as the most effective medicine for this use. The issue of black box warnings and potential suicidality will be addressed as well as available alternative and adjunctive medications. Drug choice\, length of initial trials\, and withdrawal strategies will also be addressed. Finally\, we will discuss the TORDIA study. Its results will enable a detailed account of augmentation strategies when fluoxetine therapy is found to be insufficient.
Course Includes\:
Live Q&\;A
Presentation Handout
Post session recording access
CE Credit
What You Will Learn\:
Examine the unique use of fluoxetine therapy in child and adolescent depression as well as its limitations
Define the origins of early age depression and the mechanisms involved
Recognize that preschool depression is a real phenomenon and not a developmentally transient disorder
Discuss the later life consequences of untreated depression in children and early-age adolescents
Identify why adjunctive medication therapy may be needed for resistant depression
Your Presenter\:
Robert M. Julien\, MD\, PhD\, is both an anesthesiologist and psychopharmacologist with over 40 years of experience. He received his PhD from the University of Washington in 1970 and his MD from the University of California at Irvine in 1977. Previously an Associate Professor of Pharmacology and Anesthesiology at the Oregon Health Sciences University\, Dr. Julien lectures widely on psychopharmacology. With over 36 years of continuous publication\, Dr. Julien's psychopharmacology textbook\, A Primer of Drug Action (Worth Publishers)\, is regarded as the definitive textbook of psychopharmacology\, covering both psychotherapeutic agents as well as substances of abuse. Dr. Julien is a nationally recognized speaker and expert in psychopharmacology.
Disclaimer\:
This event qualifies for one CE credit. Only registered attendees will have access to CE. A Cross Country Education web account is required to attend. There is no charge for a CCE web account. It is recommended that you join the meeting 15 to 20 minutes early. Speaker phone sound quality is poor and it is recommended that they not be used to listen to the event.
Technical requirements\:
To view this webinar you will need to download the WebEx Application. You will be prompted to download it when you first enter the site. To save time\, you can setup prior to the meeting by following this link\: https\://apidemoeu.webex.com/apidemoeu/meetingcenter/mcsetup.php
Who Should Attend\:
Pharmacists\, Psychologists\, Social Workers\, Counselors\, Drug and Alcohol Counselors\, Marriage and Family Therapists\, Case Managers\, Nurse Practitioners